US20050164292A1 - Efficient synthesis of protein-oligonucleotide conjugates - Google Patents

Efficient synthesis of protein-oligonucleotide conjugates Download PDF

Info

Publication number
US20050164292A1
US20050164292A1 US11/085,219 US8521905A US2005164292A1 US 20050164292 A1 US20050164292 A1 US 20050164292A1 US 8521905 A US8521905 A US 8521905A US 2005164292 A1 US2005164292 A1 US 2005164292A1
Authority
US
United States
Prior art keywords
protein
oligonucleotide
group
conjugate
amino group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/085,219
Inventor
Firdous Farooqui
Parameswara Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beckman Coulter Inc
Original Assignee
Beckman Coulter Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beckman Coulter Inc filed Critical Beckman Coulter Inc
Priority to US11/085,219 priority Critical patent/US20050164292A1/en
Assigned to BECKMAN COULTER, INC. reassignment BECKMAN COULTER, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FAROOQUI, FIRDOUS, REDDY, M. PARAMESWARA
Publication of US20050164292A1 publication Critical patent/US20050164292A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense

Definitions

  • the present invention is in the field of chemistry and biotechnology.
  • the present invention relates to an improved method for forming a protein-oligonucleotide conjugate.
  • the method is particularly amenable for forming antibody-oligonucleotide conjugates.
  • the invention further concerns the conjugate molecules produced using such improved methods.
  • assays include high-resolution agarose gel electrophoresis and test procedures based on the catalytic activity of endogeneous enzymes (Bhattacharyya S. P., et al., “Structural analysis of DNA cleaved in vivo by bacteriophage T4 terminase,” Gene Aug.
  • Bioconjugates such as protein-oligonucleotide conjugates, are employed in a wide variety of molecular biology applications (see, Reddy, U.S. Pat. No. 5,648,213). They are used in diagnostic assays to improve assay sensitivity (U.S. Pat. No. 6,197,513 (Coull, et al.).
  • conjugates have traditionally been prepared by methods, such as glutaraldehyde crosslinking, maleimide-thiol coupling (Ghosh S S, et al., “Use of maleimide-thiol coupling chemistry for efficient syntheses of oligonucleotide-enzyme conjugate hybridization probes,” Bioconjug Chem 1990 January-February;1(1):71-6), isothiocyanate-amine coupling (Brandtzaeg, 1973, Scand. J. Immunol. 2: 273-290; Loken and Herzenberg, 1975, Annals N.Y. Acad. Sci. 254: 163-171; U.S. Pat. No. 5,648,213 (Reddy, M. P.); Keller, G. H., et al., “DNA Probes,” MacMillan Publishers Ltd., 1989), and Schiff base formation/reduction.
  • Bioconjugates have served a variety of purposes in modern research.
  • bioconjugates such as oligonucleotides conjugated to antibodies or enzymes have been used as hybridization probes in immunoassays (U.S. Pat. No. 5,648,213 (Reddy, M. P.); Ghosh S S, et al., “Use of maleimide-thiol coupling chemistry for efficient syntheses of oligonucleotide-enzyme conjugate hybridization probes,” Bioconjug Chem 1990 January-February;1(1):71-6; Keller and Manak, DNA Probes, 2nd Edition (Stockton Press, New York, 1993; Milligan et al, J. Med.
  • Oligonucleotide-antibody conjugates have also been used as probes in the development of sensitive nucleic acid-based diagnostic assays (Martin R., et al., “A highly sensitive, nonradioactive DNA labeling and detection system,” 13: Biotechniques 1990 December;9(6):762-8) (Podbielski A, et al., “Identification of group A type 1 streptococcal M protein gene by a non-radioactive oligonucleotide detection method,” 14: Med Microbiol Immunol (Berl) 1990;179(5):255-62; Carpenter W.
  • bioconjugates Despite the promise that bioconjugates hold for improving assay sensitivity and simplifying nucleic acid detection schemes, they have not become common place tools in molecular biology and diagnostic applications.
  • the preparation of bioconjugates involves multiple steps that require the protein, oligonucleotide, or both, to be modified with the appropriate linking moiety and then purified before being combined and reacted with each other. Often the modification reaction results in an unstable reactive enzyme or oligomer intermediate that must be purified and used immediately. For these and other reasons the yield of conjugate is highly variable when these techniques are used.
  • reaction times are lengthy, and several purification steps are generally needed to obtain a purified conjugate.
  • a portion of the enzymatic activity is lost due to the nature of the chemical reactions, lengthy reaction times, and numerous purification steps.
  • the present invention relates to an improved method for forming a protein-oligonucleotide conjugate.
  • the method is particularly amenable for forming antibody-oligonucleotide conjugates.
  • the invention further concerns the conjugate molecules produced using such improved methods.
  • the invention provides a method for producing an oligonucleotide-protein conjugate, wherein the method comprises conjugating an oligonucleotide-heterofunctional linker conjugate with a protein having a thiolated group formed by thiolation of an amino group of said protein;
  • the invention particularly concerns the embodiment of such methods wherein the amino group of the oligonucleotide is at the 3′ end of the oligonucleotide, wherein the amino group of the oligonucleotide is at the 5′ end of the oligonucleotide or wherein the amino group of the oligonucleotide is at an internal site of the oligonucleotide.
  • the invention further concerns the embodiments of such methods wherein the method additionally comprises forming the oligonucleotide having the 3′, 5′ or internal amino group.
  • the invention further concerns the embodiments of such methods wherein the oligonucleotide having the 3′ amino group is formed by synthesizing the oligonucleotide on a 3′-amino CPG solid support.
  • the invention further concerns the embodiments of such methods, wherein the modified amino group is C7 CPG.
  • the invention additionally concerns the embodiments of such methods wherein the first group of the heterofunctional linker is an NHS group and/or wherein the second group of the heterofunctional linker is a maleimide group.
  • the invention additionally concerns the embodiments of such methods wherein the heterofunctional linker is selected from the group consisting of Sulfo-SMCC; Sulfo-EMCS; Sulfo-GMBS; Sulfo-KMUS; Sulfo-MBS; Sulfo-SIAB; Sulfo-SMPB; Sulfo-LC-SMPT; SVSB; SIACX; SIA, SIAXX; and NPIA.
  • the invention additionally concerns the embodiments of such methods wherein the thiolated group of the protein is derived from an iminothiolane moiety and/or wherein the method additionally comprises forming the protein having the thiolated group.
  • the invention further concerns an oligonucleotide-protein conjugate produced through the process comprising conjugating an oligonucleotide-heterofunctional linker conjugate to a protein having a thiolated group formed by thiolation of an amino group of the protein;
  • the invention particularly concerns the embodiment of such oligonucleotide-protein conjugates wherein the amino group of the oligonucleotide is at the 3′ end of the oligonucleotide, wherein the amino group of the oligonucleotide is at the 5′ end of the oligonucleotide or wherein the amino group of the oligonucleotide is at an internal site of the oligonucleotide.
  • the invention further concerns the embodiment of such oligonucleotide-protein conjugates wherein the protein is an enzyme (especially alkaline phosphatase, ⁇ -galactosidase, horse radish peroxidase, or urease), hapten, immunoglobulin (especially an immunoglobulin that is able to bind to a drug, a receptor, a receptor ligand, or a tumor antigen or an immunoglobulin that is able to an antigen that is characteristic of a pathogen (e.g., a virus, bacteria or fungus), streptavidin, avidin, or a phycobillin protein.
  • an enzyme especially alkaline phosphatase, ⁇ -galactosidase, horse radish peroxidase, or urease
  • hapten especially an immunoglobulin that is able to bind to a drug, a receptor, a receptor ligand, or a tumor antigen or an immunoglobulin that is able
  • the invention further concerns a method for determining the presence or concentration of a target nucleic acid molecule in a sample which comprises:
  • the invention particularly concerns the embodiment of such method wherein the amino group is at the 3′ end of the oligonucleotide, wherein the amino group is at the 5′ end of the oligonucleotide or wherein the amino group of the oligonucleotide is at an internal site of the oligonucleotide.
  • the invention particularly concerns the embodiments of such methods wherein the protein of the oligonucleotide-protein conjugate is an enzyme (especially alkaline phosphatase, ⁇ -galactosidase, horse radish peroxidase, or urease), hapten, or immunoglobulin (especially an immunoglobulin that is able to bind to a drug, a receptor, a receptor ligand, or a tumor antigen, or an immunoglobulin that is able to an antigen that is characteristic of a pathogen.
  • an enzyme especially alkaline phosphatase, ⁇ -galactosidase, horse radish peroxidase, or urease
  • hapten or immunoglobulin (especially an immunoglobulin that is able to bind to a drug, a receptor, a receptor ligand, or a tumor antigen, or an immunoglobulin that is able to an antigen that is characteristic of a pathogen.
  • the invention particularly concerns the embodiments of such methods where the target nucleic acid molecule is a nucleic acid molecule of a pathogen or tumor cell.
  • the invention also concerns a method for determining the presence or concentration of a target analyte in a sample which comprises:
  • the invention particularly concerns the embodiments of such method wherein the protein of the oligonucleotide-protein conjugate is an enzyme, a receptor, or a receptor ligand.
  • the invention particularly concerns the embodiment of such method wherein the amino group of the oligonucleotide is at the 3′ end of the oligonucleotide, wherein the amino group of the oligonucleotide is at the 5′ end of the oligonucleotide or wherein the amino group of the oligonucleotide is at an internal site of the oligonucleotide.
  • the invention particularly concerns the embodiment of such methods wherein the protein of the oligonucleotide-protein is an enzyme, receptor, receptor ligand, tumor antigen or is characteristic of a pathogen (especially a virus, bacteria or fungus).
  • a pathogen especially a virus, bacteria or fungus
  • FIG. 1 illustrates the synthesis of an oligonucleotide-antibody conjugate.
  • the preparation begins with the synthesis of the 3′-amino oligonucleotide that is activated with a hetero-bifunctional linker sulfo SMCC.
  • Antibodies are then thiolated using Traut's reagent (iminothiolane).
  • the activated oligonucleotide and thiolated antibodies are subsequently mixed to facilitate coupling of oligonucleotide to antibody.
  • FIG. 2 illustrates the use of oligonucleotide-antibody conjugates in an IL 8 assay performed on an A 2 plate.
  • the present invention relates to an improved method for forming a protein-oligonucleotide conjugate.
  • the invention further concerns the conjugate molecules produced using such improved methods.
  • the reactions involve the covalent coupling of a thiolated amino group of a protein with an aminated group of an oligonucleotide.
  • the oligonucleotides that can be employed in accordance with the present invention may vary from 2 nucleotides in length to over several thousand nucleotides in length, and can have any sequence.
  • the oligonucleotides may be single-stranded or double-stranded, and may comprise naturally occurring nucleotide residues or may comprise modified
  • the synthesis of the oligonucleotide-protein conjugate is accomplished in four steps:
  • the amino group of the oligonucleotide may be present at the 3′ terminal residue of the oligonucleotide, at the 5′ terminal residue of the oligonucleotide, or at a site between the termini of the molecule (i.e., an internal site).
  • an amino modifier reagent such as C7 CPG (Glen Research, Sterling Va.):
  • heterofunctional linker In order to link the modified oligonucleotide to the protein, a heterofunctional linker is employed.
  • such heterofunctional linker will have one moiety (such as an NHS-ester moiety) that is able to react with the primary amine of the 3′ amino oligonucleotide and a second moiety (such as a maleimide group) that is capable of reacting with a thiol group.
  • suitable heterofunctional linkers include:
  • Sulfo-SMCC sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate
  • Sulfo-SMCC sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate
  • the linker is reacted with the amino oligonucleotide prior to its reaction with the protein. Reaction at a pH of approximately 8.0-8.5 at room temperature results in the formation of an amide bond between the amino group of the oligonucleotide and the ester carbon of the linker ( FIG. 1 ).
  • the amino group of the protein that is to be conjugated is preferably reacted with iminothiolane (Traut's reagent). Reaction at room temperature results in the formation of a thiol modification to the involved amino group ( FIG. 1 ).
  • the amino group may be the amino terminal amino group, or it may be an internal amino group (e.g., the ⁇ amino group of a lysine or arginine residue).
  • Coupling between the activated oligonucleotide and the thiolated protein is preferably accomplished by mixing the thiolated protein with the sulfo-SMCC-modified oligonucleotide. Such mixing may be conducted in phosphate buffered saline (PBS), 3 M NaCl, 2 mM EDTA.
  • PBS phosphate buffered saline
  • 3 M NaCl 3 M NaCl
  • 2 mM EDTA 3 M NaCl
  • Any protein bearing a free primary amino group can be conjugated in accordance with the methods of the present invention.
  • proteins include enzymes, hormones, solubilized receptor proteins, peptides, immunoglobulins, etc.
  • such proteins will be enzymes.
  • the enzyme By conjugating an enzyme to an oligonucleotide, the enzyme can be used to label (and hence identify the presence or concentration of) any nucleic acid molecule (DNA or RNA) in a sample that possesses a nucleotide sequence complementary in sequence to that of the conjugated oligonucleotide (see, for example, Kusunoki, S. et al., “Application of colorimetric microdilution plate hybridization for rapid genetic identification of 22 Mycobacterium species,” J Clin Microbiol. 1991 August;29(8):1596-603; Bhattacharya, S.
  • the conjugates of the present invention may be used to detect the presence or absence of a nucleic acid sought to be detected in a biological medium, which may contain other nucleic acids that are not sought.
  • Preferred methods for accomplishing such detection are described by Kourilsky et al. (U.S. Pat. Nos. 5,955,262; 5,876,928 and 5,605,800, all herein incorporate by reference) and by Avrameas et al. (U.S. Pat. No. 4,526,871)
  • Such samples may include biological samples derived from a human or other animal source (such as, for example, blood, stool, sputum, mucus, serum, urine, saliva, teardrop, a biopsy sample, a histology tissue sample, a PAP smear, a mole, a wart, an agricultural product, waste water, drinking water, milk, processed foodstuff, air, etc.) including samples derived from a bacterial or viral preparation, as well as other samples (such as, for example, agricultural products, waste or drinking water, milk or other processed foodstuff, air, etc.).
  • a human or other animal source such as, for example, blood, stool, sputum, mucus, serum, urine, saliva, teardrop, a biopsy sample, a histology tissue sample, a PAP smear, a mole, a wart, an agricultural product, waste water, drinking water, milk, processed foodstuff, air, etc.
  • samples derived from a bacterial or viral preparation as well as other samples (
  • the present invention provides a method for facilitating the detection of nucleic acid hybridization and amplification.
  • Such assays may be used to identify alleles or polymorphisms (including single nucleotide polymorphisms), or may be used to reveal the presence of nucleic acid molecules that are characteristic of pathogens (e.g., viral DNA or RNA (such DNA or RNA of the hepatitis virus, immunodeficiency viruses (HIV, FIV), rubella, EBV, CMV, influenza, etc.), or bacterial/fungal DNA or RNA (e.g., DNA or RNA of M. tuberculosi, Streptococcus pyogenes Group A bacteria, H. pylori , Chlamydia, etc.).
  • pathogens e.g., viral DNA or RNA (such DNA or RNA of the hepatitis virus, immunodeficiency viruses (HIV, FIV), rubella, EBV, CMV, influenza, etc.
  • enzymes such as alkaline phosphatase, ⁇ -galactosidase, horse radish peroxidase, urease, etc., for which chromogenic or fluorogenic substrates exist are particularly preferred.
  • Suitable substrates for peroxidase include: TMB (3,3′,5,5′ tetramethyl-benzidine), DAB (3,3′,4,4′ diaminobenzidine), and 4CN (4-chloro-1-naphthol), which produce insoluble products.
  • TMB dual function substrate
  • ABTS ABTS (2,2′-azino-di [3-ethylbenzthiazoline] sulfonate
  • OPD o-phenylenediamine
  • Suitable substrates for alkaline phosphatase include: BBT (2′-[2-benzthiazoyl]-6′-hydroxy-benzthiazole), 1,2-dioxetane chemiluminescent substrates, BCIP/NBT (5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium), and p-NPP (p-nitrophenylphosphate).
  • Suitable substrates for horse radish peroxidase include: AmplexTM Red reagent (10-acetyl-3,7-dihydroxyphenoxazine; Molecular Probes, Oregon), guaiac, 2-2′-azino-bis(3-ethyl-benthiazoline-6-sulfonic acid), tetramethylbenzidine, phenol, 4-aminoantipyrine, and 4,5-dihydroxynaphthalene-2,7-disulfonic acid (see also U.S. Pat. Nos. 6,251,621; 5,316,906; 5,443,986; and EP 0,641,351).
  • enzymatic reactions may be followed by other means (changes in pH, production of product, etc.)
  • chromogenic or fluorogenic substrates can be employed.
  • carboxy terminus of single amino acids and short peptides can be conjugated to certain amine-containing fluorophores (e.g., rhodamine 110 (R110), etc.) to create fluorogenic peptidase substrates (Lucas, et al. (U.S. Pat. No. 5,698,411) and Landrum et al. (U.S. Pat. No. 5,976,822)).
  • 7-aminocoumarins can be employed to form UV light-excitable substrates (e.g., CBZ-L-phenylalanyl-L-arginine amide of AMC) for serine proteases, including cathepsins, kallikrein and plasmin.
  • the fluorogenic t-BOC-Leu-Met-CMAC substrate can be used to measure calpain activity. Many such substates are commercially available (Molecular Probes, Inc.).
  • the protein molecule of the conjugate can alternatively be a hapten (including an antigen) molecule or moiety, that can be recognized and bound by an immunoglobulin.
  • hapten including an antigen
  • Such molecules can be directly labeled, as with radioisotopes, fluors, chemiluminescent groups or enzymes. Alternatively, they may be reacted with a labeled molecule (for example a labeled binding ligand or second immunoglobulin capable of binding to the hapten or antigen).
  • a labeled molecule for example a labeled binding ligand or second immunoglobulin capable of binding to the hapten or antigen.
  • a wide variety of such haptens or antigens may be used (e.g., enzymatic co-factors, receptors, receptor ligands, hormones, cytokines, blood factors, viruses, steroids, drugs, etc.).
  • the protein molecule of the conjugate can alternatively be an immunoglobulin, which may be labeled directly (as with radioisotopes, fluors, chemiluminescent groups or enzymes), or indirectly (as by binding to a labeled molecule).
  • immunoglobulin includes natural or artificial mono- or polyvalent antibodies and polyclonal and monoclonal antibodies, and also molecules that are fragments and derivatives of such, including, for example, F(ab′) 2 , Fab′ and Fab fragments, chimeric antibodies, hybrid antibodies having at least two antigen or epitope binding sites, single polypeptide chain antibodies, bispecific recombinant antibodies (e.g.
  • Polyclonal antibodies may be produced through any of a variety of well known methods.
  • various animals may be immunized for this purpose in known manner by injecting them with an antigen (for example the target biological molecule, or another molecule sharing an epitope of the target biological molecule.
  • an antigen for example the target biological molecule, or another molecule sharing an epitope of the target biological molecule.
  • antigen molecules may be of natural origin or obtained by DNA recombination or synthetic methods, or fragments thereof and the desired polyclonal antibodies are obtained from the resulting sera and purified by known methods.
  • intact cells that array the target biological molecule may be used.
  • Various adjuvants may also be used for increasing the immune response to the administration of antigen, depending on the animal selected for immunization.
  • adjuvants examples include Freund's adjuvant, mineral gels such as aluminum hydroxide, surfactant substances such as polyanions, peptides, oil emulsions, haemocyanins, dinitrophenol or lysolecithin.
  • the proteins used in the conjugates of the present invention may be purified to a desired degree of purity. Methods for accomplishing such purification are well known to those of ordinary skill (e.g. by immunoabsorption or immunoaffinity chromatography, by HPLC (High Performance Liquid Chromatography) or combinations thereof).
  • Suitable antibody fragments may also be prepared by known methods. For example, F(ab′) 2 fragments may be obtained by pepsin digestion of the complete polyclonal or monoclonal antibody.
  • Fab′ fragments may be obtained by reducing the disulfide bridges of the associated F(ab′) 2 fragment, for example, and Fab fragments may be obtained, for example, by treating the antibody molecules with papain and a reducing agent.
  • Such immunoglobulins may be selected for their ability to bind to drugs, receptors, receptor ligands, tumor antigens, or antigens that are characteristic of pathogens (e.g., viruses such as hepatitis virus, immunodeficiency viruses (HIV, FIV), rubella, EBV, CMV, influenza, etc., or bacteria/fungi such as M tuberculosi, Streptococcus pyogenes Group A bacteria, H. pylori , Chlamydia, etc.
  • pathogens e.g., viruses such as hepatitis virus, immunodeficiency viruses (HIV, FIV), rubella, EBV, CMV, influenza, etc.
  • bacteria/fungi such as M tuberculosi, Streptococcus pyogenes Group A bacteria, H. pylori , Chlamydia, etc.
  • the conjugates of the present invention may be used to assay for the presence of binding ligands to the conjugated protein, and the presence or concentration of such ligands detected using assays of nucleic acid amplification.
  • a conjugate can be prepared in which the protein is a receptor ligand.
  • the ligand portion of the conjugate will bind the receptor and thereby immobilize the conjugate.
  • immobilization can be detected via nucleic acid amplification technologies, or nucleic acid molecular beacon technologies.
  • nucleic acid amplification technologies including polymerase chain reaction, ligase chain reaction, rolling circle amplification, strand displacement amplification, etc. (see, for example, EP-A-439 182; EP-A-320 308; U.S. Pat. No. 4,683,194; U.S. Pat. Nos.: 4,683,202; 5,270,184; 5,427,930; 5,455,166; 5,733,733; 5,854,033; 6,124,120; 6,143,495; 6,180,338; 6,207,368; 6,218,152; 6,261,808).
  • signal amplification technologies such as branched chain nucleic acid amplification, and molecular beacon technology may be employed (see, for example, U.S. Pat. Nos. 5,854,033; 5,989,823; 6,090,552; 5,552,541 and Tyagi, et al., “Molecular beacons: probes that fluoresce upon hybridization,” Nature Biotechnol 14(3):303-8 (1996).
  • oligonucleotide-protein conjugate was synthesized in order to illustrate the principles of the present invention.
  • an antibody that binds interleukin-8 (IL-8) (anti-human IL-8/CXCL8; (MAB208, R&D Systems, Minneapolis, Minn.)) was employed as the conjugating protein.
  • 3′-Amino Oligonucleotide A 30 residue long oligonucleotide was synthesized using 3′ amino-modifier C7 CPG obtained from Glen Research (Part #20-2957-01) on a 1 ⁇ m scale. The oligonucleotide was cleaved and deprotected using Ammonia/Methylamine(1:9) for 2 hours at room temperature and then desalted using a G-25 sephadex (1.5 cm ⁇ 50 cm) column using water as an eluent. The oligonucleotide was analyzed via capillary electrophoresis.
  • Iminothiolane Traut's Reagent: 2.5 mg of antibody was activated with iminothiolane (20 ⁇ l of a 2 mg/ml solution in 1 ⁇ PBS) in 1 ml of 1 ⁇ PBS and reacted at room temperature for 2 hours.
  • the activated antibody was purified using a G-25 column (1.5 cm ⁇ 50 cm; Amersham-Pharmaceia, Piscataway, N.J.), using 1 ⁇ PBS, 5 mM EDTA as an eluent.
  • DNA Oligonucleotide-Antibody Conjugation Activated antibody was mixed with the sulfo-SMCC-modified oligonucleotide. The final concentration was 1 ⁇ PBS, 3 M NaCl, 2 mM EDTA. The resulting mixture was concentrated using centricon-3 for 3 hours and left to react at 12° C. for 1 day.
  • the conjugate was characterized on 8% PAGE and stained with stains all (1-Ethyl-2-[3-(1 -ethyinaphtho[1,2-d]-thiazolin-2-ylidene)-2-methylpropenyl]-naphthol[1,2-d]thiazolium bromide; Sigma Chemical, St. Louis, Mo.).
  • the complementary oligonucleotide was printed on a 3 ⁇ 3 “Array of Array” (“A 2 ”) plate.
  • 140 ng of the Antibody-Oligonucleotide conjugate (in casein buffer with 0.5 M salt) was added to the well and incubated for 1 hr at 37° C.
  • the plate is washed three times, and antigen is added in different concentrations ranging from 1,000 pg/ml to 1 pg/ml in 50 ⁇ l of volume. After three washings, a biotinylated second antibody conjugate is added and is allowed to react for 1 hour at 37° C.
  • porphyridium cruentun phycobilisome (SAv-PBXsl; Martek Biosciences, Columbia, Md.) is added and allowed to react for 1 hour. The plates are then washed three more times and imaged under a CCD camera. The sensitivity of the assay was found to be 1 pg/ml with IL-8 antigen (see FIG. 2 ).
  • the sample was passed through the DEAE column 3-4 times and eluted with 0.1 M Tris pH 8.6 with salt gradient of 0.05 M NaCl, 0.1 M NaCl, 0.25 M NaCl, 0.5 M NaCl and 1 M NaCl.
  • the fractions at 0.25 M and 0.5M contain the conjugates.
  • the yield of the conjugate was 50%.
  • the conjugate was characterized by PAGE analysis.

Abstract

The present invention relates to an improved method for forming a protein-oligonucleotide conjugate. The method is particularly amenable for forming antibody-oligonucleotide conjugates. The invention further concerns the conjugate molecules produced using such improved methods.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. patent application Ser. No. 10/032,592, filed Oct. 24, 2001, which application is hereby incorporated by reference in its entirety.
  • FIELD OF THE INVENTION
  • The present invention is in the field of chemistry and biotechnology. The present invention relates to an improved method for forming a protein-oligonucleotide conjugate. The method is particularly amenable for forming antibody-oligonucleotide conjugates. The invention further concerns the conjugate molecules produced using such improved methods.
  • BACKGROUND OF THE INVENTION
  • Assays directed to the detection and quantification of physiologically significant materials in biological fluid and tissue samples are important tools in scientific research and in the health care field.
  • Several different types of assay have been developed that are capable of detecting relatively high concentrations of components of common biological samples such as human serum (Zhang T. H., et al., “Detection for anti-hantavirus IgM in patient serum with silver enhanced dot immunogold filtration assay,” Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2000 September;14(3):266-7). Such assays include high-resolution agarose gel electrophoresis and test procedures based on the catalytic activity of endogeneous enzymes (Bhattacharyya S. P., et al., “Structural analysis of DNA cleaved in vivo by bacteriophage T4 terminase,” Gene Aug. 19, 1994;146(1):67-72; Gaillot O.,et al., “Molecular characterization and expression analysis of the superoxide dismutase gene from Streptococcus agalactiae,” Gene Dec. 19, 1997;204(1-2):213-8; Trigueros S., et al., “Novel display of knotted DNA molecules by two-dimensional gel electrophoresis,” Nucleic Acids Res Jul. 1, 2001;29(13):E67-7). These methods generally do not have the sensitivity required to detect and quantify the numerous other physiologically important sample constituents which may be present at very low concentrations (e.g., endogeneous molecules intimately involved in cellular regulation (hormones, steroids, biochemical messengers); basic structural components of the organism (amino acids, proteins, polysaccharides); genetic material (DNA, RNA); vitamins, drugs and drug metabolites; toxins, pathogens and substances generated by the immune system).
  • Bioconjugates, such as protein-oligonucleotide conjugates, are employed in a wide variety of molecular biology applications (see, Reddy, U.S. Pat. No. 5,648,213). They are used in diagnostic assays to improve assay sensitivity (U.S. Pat. No. 6,197,513 (Coull, et al.). Such conjugates have traditionally been prepared by methods, such as glutaraldehyde crosslinking, maleimide-thiol coupling (Ghosh S S, et al., “Use of maleimide-thiol coupling chemistry for efficient syntheses of oligonucleotide-enzyme conjugate hybridization probes,” Bioconjug Chem 1990 January-February;1(1):71-6), isothiocyanate-amine coupling (Brandtzaeg, 1973, Scand. J. Immunol. 2: 273-290; Loken and Herzenberg, 1975, Annals N.Y. Acad. Sci. 254: 163-171; U.S. Pat. No. 5,648,213 (Reddy, M. P.); Keller, G. H., et al., “DNA Probes,” MacMillan Publishers Ltd., 1989), and Schiff base formation/reduction.
  • Bioconjugates have served a variety of purposes in modern research. For example, bioconjugates such as oligonucleotides conjugated to antibodies or enzymes have been used as hybridization probes in immunoassays (U.S. Pat. No. 5,648,213 (Reddy, M. P.); Ghosh S S, et al., “Use of maleimide-thiol coupling chemistry for efficient syntheses of oligonucleotide-enzyme conjugate hybridization probes,” Bioconjug Chem 1990 January-February;1(1):71-6; Keller and Manak, DNA Probes, 2nd Edition (Stockton Press, New York, 1993; Milligan et al, J. Med. Chem., 36: 1923-1937 (1993); Drmanac et al, Science, 260: 1649-1652 (1993); Bains, J. DNA Sequencing and Mapping, 4: 143-150 (1993)). Oligonucleotide-antibody conjugates have also been used as probes in the development of sensitive nucleic acid-based diagnostic assays (Martin R., et al., “A highly sensitive, nonradioactive DNA labeling and detection system,” 13: Biotechniques 1990 December;9(6):762-8) (Podbielski A, et al., “Identification of group A type 1 streptococcal M protein gene by a non-radioactive oligonucleotide detection method,” 14: Med Microbiol Immunol (Berl) 1990;179(5):255-62; Carpenter W. R., et al., “A transcriptionally amplified DNA probe assay with ligatable probes and immunochemical detection,” 9: Clin Chem 1993 September;39(9):1934-8). Other bioconjugates, such as isothiocyanates (ITCs) conjugates, are used in bioassays as versatile chemopreventive agents (Chung E. L., “Chemoprevention of lung cancer by isothiocyanates and their conjugates in A/J mouse,” Exp Lung Res 2001 April-May;27(3):319-30). Protein-polysaccharide conjugates with reciprocally enhanced immunogenicity have been used in the development of combination vaccines (Gupta R. K., et al., “Adjuvants for human vaccines—current status, problems and future prospects,” Vaccine 1995 October;13(14):1263-76).
  • Despite the promise that bioconjugates hold for improving assay sensitivity and simplifying nucleic acid detection schemes, they have not become common place tools in molecular biology and diagnostic applications. The preparation of bioconjugates involves multiple steps that require the protein, oligonucleotide, or both, to be modified with the appropriate linking moiety and then purified before being combined and reacted with each other. Often the modification reaction results in an unstable reactive enzyme or oligomer intermediate that must be purified and used immediately. For these and other reasons the yield of conjugate is highly variable when these techniques are used. Furthermore, reaction times are lengthy, and several purification steps are generally needed to obtain a purified conjugate. Finally, in most instances a portion of the enzymatic activity is lost due to the nature of the chemical reactions, lengthy reaction times, and numerous purification steps.
  • For these reasons direct conjugates are expensive and difficult to make with reproducible results. This has prevented them from becoming commonplace tools in molecular biology and diagnostic applications despite the promise they hold for improving assay sensitivity and simplifying nucleic acid detection schemes.
  • Despite such efforts, a need continues for methods that provide a more efficient conjugation of an oligonucleotide to an antibody to improve the sensitivity of oligonucleotide-antibody conjugates as reagents in immunoassays. The present invention is directed to such a need.
  • SUMMARY OF THE INVENTION
  • The present invention relates to an improved method for forming a protein-oligonucleotide conjugate. The method is particularly amenable for forming antibody-oligonucleotide conjugates. The invention further concerns the conjugate molecules produced using such improved methods.
  • In detail, the invention provides a method for producing an oligonucleotide-protein conjugate, wherein the method comprises conjugating an oligonucleotide-heterofunctional linker conjugate with a protein having a thiolated group formed by thiolation of an amino group of said protein;
      • wherein:
      • the linker is conjugated to the oligonucleotide by a chemical bond formed between an atom of a first group of the linker and an amino group of the oligonucleotide, and wherein the linker possesses a second group that is reactive with the thiolated group of the protein and forms a chemical bond therewith.
  • The invention particularly concerns the embodiment of such methods wherein the amino group of the oligonucleotide is at the 3′ end of the oligonucleotide, wherein the amino group of the oligonucleotide is at the 5′ end of the oligonucleotide or wherein the amino group of the oligonucleotide is at an internal site of the oligonucleotide.
  • The invention further concerns the embodiments of such methods wherein the method additionally comprises forming the oligonucleotide having the 3′, 5′ or internal amino group.
  • The invention further concerns the embodiments of such methods wherein the oligonucleotide having the 3′ amino group is formed by synthesizing the oligonucleotide on a 3′-amino CPG solid support.
  • The invention further concerns the embodiments of such methods, wherein the modified amino group is C7 CPG.
  • The invention additionally concerns the embodiments of such methods wherein the first group of the heterofunctional linker is an NHS group and/or wherein the second group of the heterofunctional linker is a maleimide group. The invention additionally concerns the embodiments of such methods wherein the heterofunctional linker is selected from the group consisting of Sulfo-SMCC; Sulfo-EMCS; Sulfo-GMBS; Sulfo-KMUS; Sulfo-MBS; Sulfo-SIAB; Sulfo-SMPB; Sulfo-LC-SMPT; SVSB; SIACX; SIA, SIAXX; and NPIA.
  • The invention additionally concerns the embodiments of such methods wherein the thiolated group of the protein is derived from an iminothiolane moiety and/or wherein the method additionally comprises forming the protein having the thiolated group.
  • The invention further concerns an oligonucleotide-protein conjugate produced through the process comprising conjugating an oligonucleotide-heterofunctional linker conjugate to a protein having a thiolated group formed by thiolation of an amino group of the protein;
      • wherein:
      • the linker is conjugated to the oligonucleotide by a chemical bond formed between an atom of a first group of the linker and an amino group of the oligonucleotide, and wherein the linker possesses a second group that is reactive with the thiolated group of the protein and forms a chemical bond therewith.
  • The invention particularly concerns the embodiment of such oligonucleotide-protein conjugates wherein the amino group of the oligonucleotide is at the 3′ end of the oligonucleotide, wherein the amino group of the oligonucleotide is at the 5′ end of the oligonucleotide or wherein the amino group of the oligonucleotide is at an internal site of the oligonucleotide.
  • The invention further concerns the embodiment of such oligonucleotide-protein conjugates wherein the protein is an enzyme (especially alkaline phosphatase, β-galactosidase, horse radish peroxidase, or urease), hapten, immunoglobulin (especially an immunoglobulin that is able to bind to a drug, a receptor, a receptor ligand, or a tumor antigen or an immunoglobulin that is able to an antigen that is characteristic of a pathogen (e.g., a virus, bacteria or fungus), streptavidin, avidin, or a phycobillin protein.
  • The invention further concerns a method for determining the presence or concentration of a target nucleic acid molecule in a sample which comprises:
      • (I) contacting the sample with an oligonucleotide-protein conjugate, wherein a sequence of an oligonucleotide portion of the conjugate is selected to be able to hybridize with the target nucleic acid molecule, wherein the oligonucleotide-protein conjugate is produced through the process comprising conjugating the oligonucleotide-heterofunctional linker conjugate with a protein having a thiolated group formed by thiolation of an amino group of the protein;
        • wherein:
        • the linker is conjugated to the oligonucleotide by a chemical bond formed between an atom of a first group of the linker and an amino group of the oligonucleotide, and wherein the linker possesses a second group that is reactive with the thiolated group of the protein and forms a chemical bond therewith; and
      • (II) detecting a protein portion of oligonucleotide-protein conjugate having an oligonucleotide portion hybridized to the target nucleic acid molecule; wherein the detection determines the presence or concentration of the target nucleic acid molecule in the sample.
  • The invention particularly concerns the embodiment of such method wherein the amino group is at the 3′ end of the oligonucleotide, wherein the amino group is at the 5′ end of the oligonucleotide or wherein the amino group of the oligonucleotide is at an internal site of the oligonucleotide.
  • The invention particularly concerns the embodiments of such methods wherein the protein of the oligonucleotide-protein conjugate is an enzyme (especially alkaline phosphatase, β-galactosidase, horse radish peroxidase, or urease), hapten, or immunoglobulin (especially an immunoglobulin that is able to bind to a drug, a receptor, a receptor ligand, or a tumor antigen, or an immunoglobulin that is able to an antigen that is characteristic of a pathogen.
  • The invention particularly concerns the embodiments of such methods where the target nucleic acid molecule is a nucleic acid molecule of a pathogen or tumor cell.
  • The invention also concerns a method for determining the presence or concentration of a target analyte in a sample which comprises:
      • (I) contacting the sample with an oligonucleotide-protein conjugate, wherein a protein portion of the conjugate is selected to be able to bind to the target analyte, wherein the oligonucleotide-protein conjugate is produced through the process comprising conjugating the oligonucleotide-heterofunctional linker conjugate with a protein having a thiolated group formed by thiolation of an amino group of the protein;
        • wherein:
        • the linker is conjugated to the oligonucleotide by a chemical bond formed between an atom of a first group of the linker and an amino group of the oligonucleotide, and wherein the linker possesses a second group that is reactive with the thiolated group of the protein and forms a chemical bond therewith.
      • (II) detecting an oligonucleotide portion of oligonucleotide-protein conjugate having a protein portion bound to the target analyte;
        • wherein the detection determines the presence or concentration of the target analyte in the sample.
  • The invention particularly concerns the embodiments of such method wherein the protein of the oligonucleotide-protein conjugate is an enzyme, a receptor, or a receptor ligand.
  • The invention particularly concerns the embodiment of such method wherein the amino group of the oligonucleotide is at the 3′ end of the oligonucleotide, wherein the amino group of the oligonucleotide is at the 5′ end of the oligonucleotide or wherein the amino group of the oligonucleotide is at an internal site of the oligonucleotide.
  • The invention particularly concerns the embodiment of such methods wherein the protein of the oligonucleotide-protein is an enzyme, receptor, receptor ligand, tumor antigen or is characteristic of a pathogen (especially a virus, bacteria or fungus).
  • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 illustrates the synthesis of an oligonucleotide-antibody conjugate. The preparation begins with the synthesis of the 3′-amino oligonucleotide that is activated with a hetero-bifunctional linker sulfo SMCC. Antibodies are then thiolated using Traut's reagent (iminothiolane). The activated oligonucleotide and thiolated antibodies are subsequently mixed to facilitate coupling of oligonucleotide to antibody.
  • FIG. 2 illustrates the use of oligonucleotide-antibody conjugates in an IL 8 assay performed on an A2 plate.
  • DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • The present invention relates to an improved method for forming a protein-oligonucleotide conjugate. The invention further concerns the conjugate molecules produced using such improved methods.
  • The reactions involve the covalent coupling of a thiolated amino group of a protein with an aminated group of an oligonucleotide. The oligonucleotides that can be employed in accordance with the present invention may vary from 2 nucleotides in length to over several thousand nucleotides in length, and can have any sequence. The oligonucleotides may be single-stranded or double-stranded, and may comprise naturally occurring nucleotide residues or may comprise modified
  • In accordance with the most preferred embodiments of the present invention (see FIG. 1), the synthesis of the oligonucleotide-protein conjugate is accomplished in four steps:
      • 1. Synthesis of an oligonucleotide having an amino group;
      • 2. Activation of the 3′ amino group by a heterofunctional linker;
      • 3. Thiolation of an amino group of the protein to be coupled; and
      • 4. Coupling of the activated oligonucleotide and the thiolated protein.
  • Such a procedure is simpler, and provides higher yields than the method of Yarmush et al. in which a thiol group is introduced at the 5′ or 3′ end of oligonucleotide and the thiolated oligonucleotide is then reacted with a protein via disulfide bond conjugation chemistry (Yarmush, M. L. et al., Bioconjugate Chemistry 8:935-940 (1997)). It is likewise superior to the method of Hendrickson et al. in which a 5′ amino oligonucleotide (activated with N˜succinimidyl thioacetate) is conjugated to an antibody that has been derivatized with sulfo-SMCC (Hendrickson, R. E. et al., Nucl., Acids Res. 23:522-529 (1994)), as well as to the method of Reddy et al. and Keller et al. in which a 5′ or 3′ amino oligonucleotide activated with 1,4 phenylene di-isothiocyanate is reacted with an antibody (Reddy, M. P. et al., U.S. Pat. No. 5,648,213 and Keller, G. H. et al., DNA Probes, MacMillan Publishers, Ltd. 1989) or an Fab' fragment of an antibody and coupled together using SMCC chemistry (Reddy, M. P. et al., U.S. Pat. No. 5,648,213).
  • The amino group of the oligonucleotide may be present at the 3′ terminal residue of the oligonucleotide, at the 5′ terminal residue of the oligonucleotide, or at a site between the termini of the molecule (i.e., an internal site).
  • The synthesis of an oligonucleotide having an amino group is preferably accomplished using an amino modifier reagent such as C7 CPG (Glen Research, Sterling Va.):
    Figure US20050164292A1-20050728-C00001
  • In order to link the modified oligonucleotide to the protein, a heterofunctional linker is employed. Preferably, such heterofunctional linker will have one moiety (such as an NHS-ester moiety) that is able to react with the primary amine of the 3′ amino oligonucleotide and a second moiety (such as a maleimide group) that is capable of reacting with a thiol group. Examples of suitable heterofunctional linkers include:
    • Sulfo-SMCC sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate
    • Sulfo-EMCS N-(ε-Maleimidocaproyloxy) sulfosuccinimide ester
    • Sulfo-GMBS (N-(γ-Maleimidobutyryloxy) sulfosuccinimide ester
    • Sulfo-KMUS N-(K-Maleimidoundecanecanoyloxy) sulfosuccinimide ester
    • Sulfo-LC-SPDP sulfosuccinimidyl 6-(3′-(2-pyridyldithio)-propionamido)hexanoate
    • Sulfo-MBS m-Maleimidobenzoyl-N-hydroxysulfosuccinimide ester
    • Sulfo-SIAB sulfosuccinimidyl(4-iodoacetyl)aminobenzoate
    • Sulfo-SMPB sulfosuccinimidyl 4-(p-maleimidophenyl)butyrate
    • Sulfo-LC-SMPT sulfosuccinimidyl-6-(α-methyl-α-(2-pyridyldithio)toluamido)hexanoate
    • SVSB (N-succinimidyl-4-vinylsulfonyl)benzoate
    • SIA N-succinimidyl iodoacetate or iodoacetic acid N-hydroxysuccinimide ester
    • SIACX (succinimidyl 6-(4-iodoacetyl)amino methyl-cyclohexane-1-carbonyl)amino hexanoate
    • SIAXX succinimidyl 6(6-(((iodoacetyl)amino hexanoyl)aminohexanoate))
    • NPIA p-nitrophenyl iodoacetate
  • All of these reagents can be purchased from Pierce, Rockford, Ill.). Sulfo-SMCC (sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate) is a preferred heterofunctional linker. The use of this compound is described by Samoszuk, M. K., et al. (“A peroxide-generating immunoconjugate directed to eosinophil peroxidase is cytotoxic to Hodgkin's disease cells in vitro,” Antibody, Immunoconjugates Radiopharmaceuticals 2(1), 37-45 (1989)):
    Figure US20050164292A1-20050728-C00002
  • Preferably, the linker is reacted with the amino oligonucleotide prior to its reaction with the protein. Reaction at a pH of approximately 8.0-8.5 at room temperature results in the formation of an amide bond between the amino group of the oligonucleotide and the ester carbon of the linker (FIG. 1).
  • The amino group of the protein that is to be conjugated is preferably reacted with iminothiolane (Traut's reagent). Reaction at room temperature results in the formation of a thiol modification to the involved amino group (FIG. 1). The amino group may be the amino terminal amino group, or it may be an internal amino group (e.g., the ε amino group of a lysine or arginine residue).
  • Coupling between the activated oligonucleotide and the thiolated protein is preferably accomplished by mixing the thiolated protein with the sulfo-SMCC-modified oligonucleotide. Such mixing may be conducted in phosphate buffered saline (PBS), 3 M NaCl, 2 mM EDTA.
  • Any protein bearing a free primary amino group can be conjugated in accordance with the methods of the present invention. Such proteins include enzymes, hormones, solubilized receptor proteins, peptides, immunoglobulins, etc.
  • In one embodiment, such proteins will be enzymes. By conjugating an enzyme to an oligonucleotide, the enzyme can be used to label (and hence identify the presence or concentration of) any nucleic acid molecule (DNA or RNA) in a sample that possesses a nucleotide sequence complementary in sequence to that of the conjugated oligonucleotide (see, for example, Kusunoki, S. et al., “Application of colorimetric microdilution plate hybridization for rapid genetic identification of 22 Mycobacterium species,” J Clin Microbiol. 1991 August;29(8):1596-603; Bhattacharya, S. et al., “Distinction of Mycobacterium tuberculosis from other mycobacteria through DNA hybridization,” Indian J Med Res. 1988 Feburary;87: 144-50; Ezaki, T. “Rapid genetic identification system of mycobacteria,” Kekkaku. 1992 December; 67(12):803-8; Ezaki, T. et al., “Quantitative microdilution plate hybridization to determine genetic relatedness among bacterial strains,” Nippon Saikingaku Zasshi. 1990 September;45(5):851-7; Ezaki, T. et al., “Simple genetic method to identify viridans group streptococci by colorimetric dot hybridization and fluorometric hybridization in microdilution wells,” J Clin Microbiol. 1988 September;26(9):1708-13; Cho, S. N. et al. “Colorimetric microwell plate hybridization assay for detection of amplified Mycobacterium tuberculosis DNA from sputum samples,” J. Clin Microbiol. 1995 March;33(3):752-4; Spargo, C. A. et al., “Chemiluminescent detection of strand displacement amplified DNA from species comprising the Mycobacterium tuberculosis complex,” Mol Cell Probes. 1993 October;7(5):395-404). Thus, the conjugates of the present invention may be used to detect the presence or absence of a nucleic acid sought to be detected in a biological medium, which may contain other nucleic acids that are not sought. Preferred methods for accomplishing such detection are described by Kourilsky et al. (U.S. Pat. Nos. 5,955,262; 5,876,928 and 5,605,800, all herein incorporate by reference) and by Avrameas et al. (U.S. Pat. No. 4,526,871)
  • Such samples may include biological samples derived from a human or other animal source (such as, for example, blood, stool, sputum, mucus, serum, urine, saliva, teardrop, a biopsy sample, a histology tissue sample, a PAP smear, a mole, a wart, an agricultural product, waste water, drinking water, milk, processed foodstuff, air, etc.) including samples derived from a bacterial or viral preparation, as well as other samples (such as, for example, agricultural products, waste or drinking water, milk or other processed foodstuff, air, etc.).
  • In one embodiment, the present invention provides a method for facilitating the detection of nucleic acid hybridization and amplification. Such assays may be used to identify alleles or polymorphisms (including single nucleotide polymorphisms), or may be used to reveal the presence of nucleic acid molecules that are characteristic of pathogens (e.g., viral DNA or RNA (such DNA or RNA of the hepatitis virus, immunodeficiency viruses (HIV, FIV), rubella, EBV, CMV, influenza, etc.), or bacterial/fungal DNA or RNA (e.g., DNA or RNA of M. tuberculosi, Streptococcus pyogenes Group A bacteria, H. pylori, Chlamydia, etc.).
  • For such purposes, enzymes such as alkaline phosphatase, β-galactosidase, horse radish peroxidase, urease, etc., for which chromogenic or fluorogenic substrates exist are particularly preferred. Suitable substrates for peroxidase include: TMB (3,3′,5,5′ tetramethyl-benzidine), DAB (3,3′,4,4′ diaminobenzidine), and 4CN (4-chloro-1-naphthol), which produce insoluble products. Also suitable are TMB (dual function substrate), ABTS (2,2′-azino-di [3-ethylbenzthiazoline] sulfonate), and OPD (o-phenylenediamine), which produce soluble products. Suitable substrates for alkaline phosphatase include: BBT (2′-[2-benzthiazoyl]-6′-hydroxy-benzthiazole), 1,2-dioxetane chemiluminescent substrates, BCIP/NBT (5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium), and p-NPP (p-nitrophenylphosphate). Suitable substrates for horse radish peroxidase include: Amplex™ Red reagent (10-acetyl-3,7-dihydroxyphenoxazine; Molecular Probes, Oregon), guaiac, 2-2′-azino-bis(3-ethyl-benthiazoline-6-sulfonic acid), tetramethylbenzidine, phenol, 4-aminoantipyrine, and 4,5-dihydroxynaphthalene-2,7-disulfonic acid (see also U.S. Pat. Nos. 6,251,621; 5,316,906; 5,443,986; and EP 0,641,351). In lieu of chromogenic substrates, enzymatic reactions may be followed by other means (changes in pH, production of product, etc.)
  • Although such enzymes are preferred, other enzymes can be similarly exploited, and a wide variety of chromogenic or fluorogenic substrates can be employed. For example, the carboxy terminus of single amino acids and short peptides can be conjugated to certain amine-containing fluorophores (e.g., rhodamine 110 (R110), etc.) to create fluorogenic peptidase substrates (Lucas, et al. (U.S. Pat. No. 5,698,411) and Landrum et al. (U.S. Pat. No. 5,976,822)). In addition 7-aminocoumarins (AMC) can be employed to form UV light-excitable substrates (e.g., CBZ-L-phenylalanyl-L-arginine amide of AMC) for serine proteases, including cathepsins, kallikrein and plasmin. The fluorogenic t-BOC-Leu-Met-CMAC substrate can be used to measure calpain activity. Many such substates are commercially available (Molecular Probes, Inc.).
  • The protein molecule of the conjugate can alternatively be a hapten (including an antigen) molecule or moiety, that can be recognized and bound by an immunoglobulin. Such molecules can be directly labeled, as with radioisotopes, fluors, chemiluminescent groups or enzymes. Alternatively, they may be reacted with a labeled molecule (for example a labeled binding ligand or second immunoglobulin capable of binding to the hapten or antigen). A wide variety of such haptens or antigens may be used (e.g., enzymatic co-factors, receptors, receptor ligands, hormones, cytokines, blood factors, viruses, steroids, drugs, etc.).
  • The protein molecule of the conjugate can alternatively be an immunoglobulin, which may be labeled directly (as with radioisotopes, fluors, chemiluminescent groups or enzymes), or indirectly (as by binding to a labeled molecule). As used herein, the term “immunoglobulin” includes natural or artificial mono- or polyvalent antibodies and polyclonal and monoclonal antibodies, and also molecules that are fragments and derivatives of such, including, for example, F(ab′)2, Fab′ and Fab fragments, chimeric antibodies, hybrid antibodies having at least two antigen or epitope binding sites, single polypeptide chain antibodies, bispecific recombinant antibodies (e.g. quadromes, triomes), interspecies hybrid antibodies, and molecules that have been chemically modified and must be regarded as derivatives of such molecules and which may be prepared either by the known conventional methods of antibody production or by DNA recombination, using hybridoma techniques or antibody engineering or synthetically or semisynthetically in known manner. Methods for isolating or obtaining immunoglobulins are well-known in the art (Kohler, G. & Milstein, C., Nature 256:495-497 (1975); Taggart & Samloff, Science 219:1228-1230 (1983); Kozbor et al., Immunology Today 4:72-79 (1983); Morrison et al., Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984); Takeda et al., Nature 314:452-454 (1985)); Biocca, S. et al., EMBO J. 9:101-108 (1990); Bird, R. E. et al., Science 242:423-426 (1988); Boss, M. A. et al., Nucl. Acids Res. 12:3791-3806 (1984); Boulianne, G. L. et al., Nature 312:643-446 (1984); Bukovsky, J. & Kennett, R. H., Hybridoma 6:219-228 (1987); Diano, M. et al., Anal. Biochem. 166:223-229 (1987); Huston J. S. et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); Jones, P. T. et al., Nature 321:522-525 (1986); Langone, J. J. & Vunakis, H. V. (Editor), Methods Enzymol. 121, Academic Press, London (1987); Morrison, S. et al., Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984); Oi, V. T. & Morrison, S. L., BioTechniques 4:214-221 (1986); Riechmann, L. et al., Nature 332:323-327 (1988); Tramontano, A. et al., Proc. Natl. Acad. Sci. USA 83:6736-6740 (1986); Wood, C. R. et al., Nature 314:446-449(1985); and Ladner, U.S. Pat. No. 4,946,778, issued Aug. 7, 1990.
  • Polyclonal antibodies may be produced through any of a variety of well known methods. For example, various animals may be immunized for this purpose in known manner by injecting them with an antigen (for example the target biological molecule, or another molecule sharing an epitope of the target biological molecule. Such antigen molecules may be of natural origin or obtained by DNA recombination or synthetic methods, or fragments thereof and the desired polyclonal antibodies are obtained from the resulting sera and purified by known methods. Alternatively, intact cells that array the target biological molecule may be used. Various adjuvants may also be used for increasing the immune response to the administration of antigen, depending on the animal selected for immunization. Examples of these adjuvants include Freund's adjuvant, mineral gels such as aluminum hydroxide, surfactant substances such as polyanions, peptides, oil emulsions, haemocyanins, dinitrophenol or lysolecithin.
  • If desired, the proteins used in the conjugates of the present invention may be purified to a desired degree of purity. Methods for accomplishing such purification are well known to those of ordinary skill (e.g. by immunoabsorption or immunoaffinity chromatography, by HPLC (High Performance Liquid Chromatography) or combinations thereof). Suitable antibody fragments may also be prepared by known methods. For example, F(ab′)2 fragments may be obtained by pepsin digestion of the complete polyclonal or monoclonal antibody. Fab′ fragments may be obtained by reducing the disulfide bridges of the associated F(ab′)2 fragment, for example, and Fab fragments may be obtained, for example, by treating the antibody molecules with papain and a reducing agent.
  • Such immunoglobulins may be selected for their ability to bind to drugs, receptors, receptor ligands, tumor antigens, or antigens that are characteristic of pathogens (e.g., viruses such as hepatitis virus, immunodeficiency viruses (HIV, FIV), rubella, EBV, CMV, influenza, etc., or bacteria/fungi such as M tuberculosi, Streptococcus pyogenes Group A bacteria, H. pylori, Chlamydia, etc.
  • In a second embodiment, the conjugates of the present invention may be used to assay for the presence of binding ligands to the conjugated protein, and the presence or concentration of such ligands detected using assays of nucleic acid amplification. Thus, for example, a conjugate can be prepared in which the protein is a receptor ligand. In the presence of the relevant receptor, the ligand portion of the conjugate will bind the receptor and thereby immobilize the conjugate. Such immobilization can be detected via nucleic acid amplification technologies, or nucleic acid molecular beacon technologies.
  • Any of a variety of nucleic acid amplification technologies may be employed, including polymerase chain reaction, ligase chain reaction, rolling circle amplification, strand displacement amplification, etc. (see, for example, EP-A-439 182; EP-A-320 308; U.S. Pat. No. 4,683,194; U.S. Pat. Nos.: 4,683,202; 5,270,184; 5,427,930; 5,455,166; 5,733,733; 5,854,033; 6,124,120; 6,143,495; 6,180,338; 6,207,368; 6,218,152; 6,261,808). Additionally, signal amplification technologies such as branched chain nucleic acid amplification, and molecular beacon technology may be employed (see, for example, U.S. Pat. Nos. 5,854,033; 5,989,823; 6,090,552; 5,552,541 and Tyagi, et al., “Molecular beacons: probes that fluoresce upon hybridization,” Nature Biotechnol 14(3):303-8 (1996).
  • Having now generally described the invention, the same will be more readily understood through reference to the following examples, which are provided by way of illustration, and are not intended to be limiting of the present invention, unless specified.
  • EXAMPLE 1 Synthesis of Oligonucleotide-Protein Conjugate
  • An oligonucleotide-protein conjugate was synthesized in order to illustrate the principles of the present invention. For such illustration, an antibody that binds interleukin-8 (IL-8) (anti-human IL-8/CXCL8; (MAB208, R&D Systems, Minneapolis, Minn.)) was employed as the conjugating protein.
  • Synthesis Of 3′-Amino Oligonucleotide: A 30 residue long oligonucleotide was synthesized using 3′ amino-modifier C7 CPG obtained from Glen Research (Part #20-2957-01) on a 1 μm scale. The oligonucleotide was cleaved and deprotected using Ammonia/Methylamine(1:9) for 2 hours at room temperature and then desalted using a G-25 sephadex (1.5 cm×50 cm) column using water as an eluent. The oligonucleotide was analyzed via capillary electrophoresis.
  • Activation Of 3′- Amino Oligonucleotide With Sulfo-SMCC: 40 Abs260 units of the above-described 3′ amino-modified oligonucleotide was activated with 4.6 mg of Sulfo-SMCC in 1 ml of 0.1 M bicarbonate buffer, pH 8.2, for 1 hour at room temperature and then purified using a sephadex G-25 column (1.5 cm×50 cm) using water as an eluent.
  • Activation Of Antibody With Iminothiolane (Traut's Reagent): 2.5 mg of antibody was activated with iminothiolane (20 μl of a 2 mg/ml solution in 1×PBS) in 1 ml of 1×PBS and reacted at room temperature for 2 hours. The activated antibody was purified using a G-25 column (1.5 cm×50 cm; Amersham-Pharmaceia, Piscataway, N.J.), using 1×PBS, 5 mM EDTA as an eluent.
  • DNA Oligonucleotide-Antibody Conjugation: Activated antibody was mixed with the sulfo-SMCC-modified oligonucleotide. The final concentration was 1×PBS, 3 M NaCl, 2 mM EDTA. The resulting mixture was concentrated using centricon-3 for 3 hours and left to react at 12° C. for 1 day.
  • Purification Of Oligonucleotide Antibody Conjugates: The above-described Antibody-Oligonucleotide conjugate was purified on a size exclusion P-100 column (1.5 cm×20 cm), using 0.1 M Tris buffer, pH 7.2, 5 mM EDTA as an eluent. Fractions that contained the first band (which had an A260/A280 ratio of 1.0-1.2) were collected, mixed and then purified on a DEAE column with a salt gradient of from 0.05 M NaCl to 1.0 M NaCl. The yield of the conjugate was 50%. The conjugate was characterized on 8% PAGE and stained with stains all (1-Ethyl-2-[3-(1 -ethyinaphtho[1,2-d]-thiazolin-2-ylidene)-2-methylpropenyl]-naphthol[1,2-d]thiazolium bromide; Sigma Chemical, St. Louis, Mo.).
  • Immunoassay Protocol: The complementary oligonucleotide was printed on a 3×3 “Array of Array” (“A2”) plate. 140 ng of the Antibody-Oligonucleotide conjugate (in casein buffer with 0.5 M salt) was added to the well and incubated for 1 hr at 37° C. The plate is washed three times, and antigen is added in different concentrations ranging from 1,000 pg/ml to 1 pg/ml in 50 μl of volume. After three washings, a biotinylated second antibody conjugate is added and is allowed to react for 1 hour at 37° C. After three additional washings, porphyridium cruentun phycobilisome (SAv-PBXsl; Martek Biosciences, Columbia, Md.) is added and allowed to react for 1 hour. The plates are then washed three more times and imaged under a CCD camera. The sensitivity of the assay was found to be 1 pg/ml with IL-8 antigen (see FIG. 2).
  • EXAMPLE 2 Synthesis of Dye Labeled Oligonucleotide-Protein Conjugate
  • Procedure to Make Dye Labeled Oligo-Antibody Conjugate:
  • The synthesis of dye labeled oligonucleotide antibody conjugate involves the following steps:
      • Synthesis of 5′ dye label 3′-amino oligonucleotide: A 30 mer oligonucleotide was synthesized on 3′-amino-modifier C7 CPG (Glen Research Part #20-2957-01) on 1 μmole scale (coupling efficiency≅98%) on ABI 394 using Apac, Gipr-pac, Cac and T phosphoramdiites. At the 5′ end Dye phosphoramidite (Cy3, or Cy3.5 or Cy5 or Cy5.5, purchased from Glen research, Sterling, Va.) was coupled using a standard protocol. The oligonucleotide was cleaved and deprotected using Ammonia for 24 hours at room temp. and purified on polypak cartridges (Glen research, Sterling, Va.). The dye labeled oligonucleotide was analyzed on CE (Beckman Pace 5000, with SSDNA gel kit).
      • Activation of 5′-dye label 3′-amino oligonucleotide with Sulfo SMCC: 40 ODs (Abs. 260 nm) of 5′-dye label 3′-amino oligonucleotide was activated with 4.6 mg of Sulfo SMCC in 1 ml of 0.1 M bicarbonate buffer, pH 8.2, for 1 hour at room temperature and purified on a Sephadex super fine DNA grade G-25 column (1.5 cm×50 cm) equilibrated with water. The desired fractions (total volume of about 6-8 ml) were mixed and the concentration was adjusted to 3 M salt (add solid NaCl), adjusted to 1×PBS (add 10×PBS); EDTA was added to a final concentration of 2 mM.
      • Activation of antibody with iminothiolane: 2.5 mg of antibody (IL8, IL4 or TNF) was dissolved in ˜1 ml of 1×PBS for at least 1 hour at room temperature and desalted on a Nap-25 column equilibrated with 1×PBS. Antibody was activated by adding iminothiolane (20 μl of 2 mg/ml solution in 1×PBS) to 1 ml of antibody in 1×PBS and reacted at room temperature for 2 hours. The activated antibody was purified on G-25 column (1.5 cm×50 cm) equilibrated with 1×PBS, 5 mM EDTA.
      • DNA oligonucleotide-Ab conjugation: Activated antibody was mixed with sulfo SMCC dye-labeled oligonucleotide, the final conc. was 1×PBS, 3 M NaCl, 2 mM EDTA. The mixture was transferred to 6-8 centricon-3, 2 ml in each centricon. The resulting mixture was concentrated for 2 hours at room temperature at 6000 rpm and then 3 hours at 12° C. at 6000 rpm and left to react for 1 day.
  • Purification of Oligonucleotide antibody conjugates: The Antibody-oligonucleotide conjugate was purified on size exclusion P-100 (Bio gel P-100 gel, 90-180 um, medium) column, 1.5 cm×20-22 cm equilibrated with 0.1 M tris buffer pH 7.4, 5 mM EDTA. Fractions containing the first peak were pooled (A260/A280 ratio=1.0-1.2), mixed, and purified on a DEAE (3 ml of gel) column. The sample was passed through the DEAE column 3-4 times and eluted with 0.1 M Tris pH 8.6 with salt gradient of 0.05 M NaCl, 0.1 M NaCl, 0.25 M NaCl, 0.5 M NaCl and 1 M NaCl. The fractions at 0.25 M and 0.5M contain the conjugates. The yield of the conjugate was 50%. The conjugate was characterized by PAGE analysis.
  • All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application had been specifically and individually indicated to be incorporated by reference. The discussion of the background to the invention herein is included to explain the context of the invention. Such explanation is not an admission that any of the material referred to was published, known, or part of the prior art or common general knowledge anywhere in the world as of the priority date of any of the aspects listed above.
  • While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth.

Claims (74)

1. A method for producing an oligonucleotide-protein conjugate, wherein said method comprises conjugating an oligonucleotide-heterofunctional linker conjugate to a protein having a thiolated group formed by thiolation of an amino group of said protein;
wherein:
said linker is conjugated to said oligonucleotide by a chemical bond formed between an atom of a first group of said linker and an amino group of said oligonucleotide, and wherein said linker possesses a second group that is reactive with said thiolated group of said protein and forms a chemical bond therewith.
2. The method of claim 1, wherein said amino group of said oligonucleotide is at the 3′ end of said oligonucleotide.
3. The method of claim 2, wherein said method additionally comprises forming said oligonucleotide having said 3′ amino group.
4. The method of claim 2, wherein said oligonucleotide having said 3′ amino group is formed by synthesizing said oligonucleotide on a 340 -amino CPG solid support.
5. The method of claim 1, wherein said amino group of said oligonucleotide is at the 5′ end of said oligonucleotide.
6. The method of claim 1, wherein said method additionally comprises forming said oligonucleotide having said 5′ amino group.
7. The method of claim 1, wherein said amino group of said oligonucleotide is at an internal site of said oligonucleotide.
8. The method of claim 7, wherein said method additionally comprises forming said oligonucleotide having said internal amino group.
9. The method of claim 1, wherein said modified amino group is C7 CPG.
10. The method of claim 1, wherein said first group of said heterofunctional linker is an NHS group.
11. The method of claim 1, wherein said second group of said heterofunctional linker is a maleimide group.
12. The method of claim 1, wherein said heterofunctional linker is selected from the group consisting of Sulfo-SMCC; Sulfo-EMCS; Sulfo-GMBS; Sulfo-KMUS; Sulfo-MBS; Sulfo-SIAB; Sulfo-SMPB; Sulfo-LC-SMPT; SVSB; SIACX; SIA, SIAXX; and NPIA.
13. The method of claim 12, wherein said heterofunctional linker is sulfo-SMCC.
14. The method of claim 1, wherein said thiolated group of said protein is derived from an iminothiolane moiety.
15. The method of claim 1, wherein said method additionally comprises forming said protein having said thiolated group.
16. The method of claim 15, wherein said thiolated group is formed by reacting the amino group of a protein with iminothiolane.
17. The method of claim 1, wherein said protein is an enzyme, hapten, immunoglobulin, streptavidin, avidin, or a phycobillin protein.
18. The method of claim 17, wherein said protein is an enzyme.
19. The method of claim 18, wherein said enzyme is selected from the group consisting of alkaline phosphatase, β-galactosidase, horse radish peroxidase, and urease.
20. The method of claim 17, wherein said protein is a hapten.
21. The method of claim 17, wherein said protein is an immunoglobulin.
22. The method of claim 21, wherein said immunoglobulin is an immunoglobulin that is able to bind to a drug, a receptor, a receptor ligand, or a tumor antigen.
23. The method of claim 21, wherein said immunoglobulin is able to bind an antigen that is characteristic of a pathogen.
24. The method of claim 23, wherein said pathogen is a virus.
25. The method of claim 24, wherein said pathogen is a bacteria or fungus.
26. The method of claim 17, wherein said protein is a streptavidin protein.
27. The method of claim 17, wherein said protein is an avidin protein.
28. The method of claim 17, wherein said protein is a phycobillin protein.
29. An oligonucleotide-protein conjugate produced through the process comprising conjugating an oligonucleotide-heterofunctional linker conjugate to a protein having a thiolated group formed by thiolation of an amino group of said protein;
wherein:
said linker is conjugated to said oligonucleotide by a chemical bond formed between an atom of a first group of said linker and an amino group of said oligonucleotide, and wherein said linker possesses a second group that is reactive with said thiolated group of said protein and forms a chemical bond therewith.
30. The oligonucleotide-protein conjugate of claim 29, wherein said amino group of said oligonucleotide is at the 3′ end of said oligonucleotide.
31. The oligonucleotide-protein conjugate of claim 29, wherein said amino group of said oligonucleotide is at the 5′ end of said oligonucleotide.
32. The oligonucleotide-protein conjugate of claim 29, wherein said amino group of said oligonucleotide is at an internal site of said oligonucleotide.
33. The oligonucleotide-protein conjugate of claim 29, wherein said protein is an enzyme, hapten, immunoglobulin, streptavidin, avidin, or a phycobillin protein.
34. The oligonucleotide-protein conjugate of claim 33, wherein said protein is an enzyme.
35. The oligonucleotide-protein conjugate of claim 34, wherein said enzyme is selected from the group consisting of alkaline phosphatase, β-galactosidase, horse radish peroxidase, and urease.
36. The oligonucleotide-protein conjugate of claim 33, wherein said protein is a hapten.
37. The oligonucleotide-protein conjugate of claim 33, wherein said protein is an immunoglobulin.
38. The oligonucleotide-protein conjugate of claim 37, wherein said immunoglobulin is an immunoglobulin that is able to bind to a drug, a receptor, a receptor ligand, or a tumor antigen.
39. The oligonucleotide-protein conjugate of claim 37, wherein said immunoglobulin is able to bind an antigen that is characteristic of a pathogen.
40. The oligonucleotide-protein conjugate of claim 39, wherein said pathogen is a virus.
41. The oligonucleotide-protein conjugate of claim 39, wherein said pathogen is a bacteria or fungus.
42. The oligonucleotide-protein conjugate of claim 33, wherein said protein is a streptavidin protein.
43. The oligonucleotide-protein conjugate of claim 33, wherein said protein is an avidin protein.
44. The oligonucleotide-protein conjugate of claim 33, wherein said protein is a phycobillin protein.
45. A method for determining the presence or concentration of a target nucleic acid molecule in a sample which comprises:
(I) contacting said sample with an oligonucleotide-protein conjugate, wherein a sequence of an oligonucleotide portion of said conjugate is selected to be able to hybridize with said target nucleic acid molecule, wherein said oligonucleotide-protein conjugate is produced through the process comprising conjugating an oligonucleotide-heterofunctional linker conjugate to a protein having a thiolated group formed by thiolation of an amino group of said protein;
wherein:
said linker is conjugated to said oligonucleotide by a chemical bond formed between an atom of a first group of said linker and an amino group of said oligonucleotide, and wherein said linker possesses a second group that is reactive with said thiolated group of said protein and forms a chemical bond therewith; and
(II) detecting a protein portion of any of said oligonucleotide-protein conjugate having an oligonucleotide portion hybridized to said target nucleic acid molecule; wherein said detection determines the presence or concentration of said target nucleic acid molecule in said sample.
46. The method of claim 45, wherein said amino group of said oligonucleotide is at the 3′ end of said oligonucleotide.
47. The method of claim 45, wherein said amino group of said oligonucleotide is at the 5′ end of said oligonucleotide.
48. The method of claim 45, wherein said amino group of said oligonucleotide is at an internal site of said oligonucleotide.
49. The method of claim 45, wherein said protein of said oligonucleotide-protein is an enzyme, hapten, immunoglobulin, streptavidin, avidin, or a phycobillin protein.
50. The method of claim 49, wherein said protein is an enzyme.
51. The method of claim 50, wherein said enzyme is selected from the group consisting of alkaline phosphatase, β-galactosidase, horse radish peroxidase, and urease.
52. The method of claim 49, wherein said protein is a hapten.
53. The method of claim 49, wherein said protein is an immunoglobulin.
54. The method of claim 53, wherein said immunoglobulin is an immunoglobulin that is able to bind to a drug, a receptor, a receptor ligand, or a tumor antigen.
55. The method of claim 53, wherein said immunoglobulin is an immunoglobulin that is able to an antigen that is characteristic of a pathogen.
56. The method of claim 55, wherein said pathogen is a virus.
57. The method of claim 55, wherein said pathogen is a bacteria or fungus.
58. The method of claim 45, wherein said target nucleic acid molecule is a nucleic acid molecule of a pathogen.
59. The method of claim 45, wherein said target nucleic acid molecule is a nucleic acid molecule of a tumor cell.
60. The method of claim 49, wherein said protein is a streptavidin protein.
61. The method of claim 49, wherein said protein is an avidin protein.
62. The method of claim 49, wherein said protein is a phycobillin protein.
63. A method for determining the presence or concentration of a target analyte in a sample which comprises:
(I) contacting said sample with an oligonucleotide-protein conjugate, wherein a protein portion of said conjugate is selected to be able to bind to said target analyte, wherein said oligonucleotide-protein conjugate is produced through the process comprising conjugating an oligonucleotide-heterofunctional linker conjugate to a protein having a thiolated group formed by thiolation of an amino group of said protein;
wherein:
said linker is conjugated to said oligonucleotide by a chemical bond formed between an atom of a first group of said linker and an amino group of said oligonucleotide, and wherein said linker possesses a second group that is reactive with said thiolated group of said protein and forms a chemical bond therewith; and
(II) detecting an oligonucleotide portion of any of said oligonucleotide-protein conjugate having a protein portion bound to said target analyte; wherein said detection determines the presence or concentration of said target analyte in said sample.
64. The method of claim 63, wherein said amino group of said oligonucleotide is at the 3′ end of said oligonucleotide.
65. The method of claim 63, wherein said amino group of said oligonucleotide is at the 5′ end of said oligonucleotide.
66. The method of claim 63, wherein said amino group of said oligonucleotide is at an internal site of said oligonucleotide.
67. The method of claim 63, wherein said protein of said oligonucleotide-protein is an enzyme, receptor or receptor ligand.
68. The method of claim 67, wherein said protein is an enzyme.
69. The method of claim 67, wherein said protein is a receptor.
70. The method of claim 67, wherein said protein is a receptor ligand.
71. The method of claim 67, wherein said protein is a tumor antigen.
72. The method of claim 53, wherein said protein is characteristic of a pathogen.
73. The method of claim 72, wherein said pathogen is a virus.
74. The method of claim 72, wherein said pathogen is a bacteria or fungus.
US11/085,219 2001-10-24 2005-03-22 Efficient synthesis of protein-oligonucleotide conjugates Abandoned US20050164292A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/085,219 US20050164292A1 (en) 2001-10-24 2005-03-22 Efficient synthesis of protein-oligonucleotide conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/032,592 US6942972B2 (en) 2001-10-24 2001-10-24 Efficient synthesis of protein-oligonucleotide conjugates
US11/085,219 US20050164292A1 (en) 2001-10-24 2005-03-22 Efficient synthesis of protein-oligonucleotide conjugates

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/032,592 Continuation US6942972B2 (en) 2001-10-24 2001-10-24 Efficient synthesis of protein-oligonucleotide conjugates

Publications (1)

Publication Number Publication Date
US20050164292A1 true US20050164292A1 (en) 2005-07-28

Family

ID=21865743

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/032,592 Expired - Lifetime US6942972B2 (en) 2001-10-24 2001-10-24 Efficient synthesis of protein-oligonucleotide conjugates
US11/085,219 Abandoned US20050164292A1 (en) 2001-10-24 2005-03-22 Efficient synthesis of protein-oligonucleotide conjugates

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/032,592 Expired - Lifetime US6942972B2 (en) 2001-10-24 2001-10-24 Efficient synthesis of protein-oligonucleotide conjugates

Country Status (4)

Country Link
US (2) US6942972B2 (en)
EP (1) EP1485500A4 (en)
AU (1) AU2002332090A1 (en)
WO (1) WO2003035830A2 (en)

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038331A1 (en) * 2002-08-23 2004-02-26 Reddy M. Parameswara Solid phase synthesis of biomolecule conjugates
US20060292559A1 (en) * 2005-06-23 2006-12-28 Beckman Coulter, Inc. Cell-based microarrays, and methods for their preparation and use
US20070212337A1 (en) * 2006-02-01 2007-09-13 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
US20090123467A1 (en) * 2007-07-31 2009-05-14 The Johns Hopkins University Polypeptide-Nucleic Acid Conjugate for Immunoprophylaxis or Immunotherapy for Neoplastic or Infectious Disorders
WO2011071943A1 (en) * 2009-12-07 2011-06-16 Prognosys Biosciences, Inc. Peptide display arrays
US9085798B2 (en) 2009-04-30 2015-07-21 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US20150218209A1 (en) * 2007-04-18 2015-08-06 Solulink, Inc. Preparation and/or Purification of Oligonucleotide Conjugates
US9222936B2 (en) 2007-04-18 2015-12-29 Solulink, Inc. Methods and/or use of oligonucleotide conjugates for suppressing background due to cross-hybridization
US9371598B2 (en) 2010-04-05 2016-06-21 Prognosys Biosciences, Inc. Spatially encoded biological assays
US9868979B2 (en) 2013-06-25 2018-01-16 Prognosys Biosciences, Inc. Spatially encoded biological assays using a microfluidic device
US9958454B2 (en) 2011-04-08 2018-05-01 Prognosys Biosciences, Inc. Peptide constructs and assay systems
US10288608B2 (en) 2013-11-08 2019-05-14 Prognosys Biosciences, Inc. Polynucleotide conjugates and methods for analyte detection
WO2020018739A1 (en) * 2018-07-18 2020-01-23 University Of Florida Research Foundation Rna silencing nanozymes
US10774374B2 (en) 2015-04-10 2020-09-15 Spatial Transcriptomics AB and Illumina, Inc. Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11092601B2 (en) 2013-03-15 2021-08-17 Prognosys Biosciences, Inc. Methods for detecting peptide/MHC/TCR binding
WO2021211791A1 (en) * 2020-04-15 2021-10-21 Academia Sinica Oligonucleotide conjugates and preparation and applications thereof
US11332790B2 (en) 2019-12-23 2022-05-17 10X Genomics, Inc. Methods for spatial analysis using RNA-templated ligation
US11352659B2 (en) 2011-04-13 2022-06-07 Spatial Transcriptomics Ab Methods of detecting analytes
US11407992B2 (en) 2020-06-08 2022-08-09 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
US11408029B2 (en) 2020-06-25 2022-08-09 10X Genomics, Inc. Spatial analysis of DNA methylation
US11434524B2 (en) 2020-06-10 2022-09-06 10X Genomics, Inc. Methods for determining a location of an analyte in a biological sample
US11519033B2 (en) 2018-08-28 2022-12-06 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample
US11535887B2 (en) 2020-04-22 2022-12-27 10X Genomics, Inc. Methods for spatial analysis using targeted RNA depletion
US11560592B2 (en) 2020-05-26 2023-01-24 10X Genomics, Inc. Method for resetting an array
US11608520B2 (en) 2020-05-22 2023-03-21 10X Genomics, Inc. Spatial analysis to detect sequence variants
US11618897B2 (en) 2020-12-21 2023-04-04 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
US11624086B2 (en) 2020-05-22 2023-04-11 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
US11649485B2 (en) 2019-01-06 2023-05-16 10X Genomics, Inc. Generating capture probes for spatial analysis
US11702698B2 (en) 2019-11-08 2023-07-18 10X Genomics, Inc. Enhancing specificity of analyte binding
US11702693B2 (en) 2020-01-21 2023-07-18 10X Genomics, Inc. Methods for printing cells and generating arrays of barcoded cells
US11733238B2 (en) 2010-04-05 2023-08-22 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11732300B2 (en) 2020-02-05 2023-08-22 10X Genomics, Inc. Increasing efficiency of spatial analysis in a biological sample
US11732299B2 (en) 2020-01-21 2023-08-22 10X Genomics, Inc. Spatial assays with perturbed cells
US11753673B2 (en) 2021-09-01 2023-09-12 10X Genomics, Inc. Methods, compositions, and kits for blocking a capture probe on a spatial array
US11761038B1 (en) 2020-07-06 2023-09-19 10X Genomics, Inc. Methods for identifying a location of an RNA in a biological sample
US11827935B1 (en) 2020-11-19 2023-11-28 10X Genomics, Inc. Methods for spatial analysis using rolling circle amplification and detection probes
US11891654B2 (en) 2020-02-24 2024-02-06 10X Genomics, Inc. Methods of making gene expression libraries
US11898205B2 (en) 2020-02-03 2024-02-13 10X Genomics, Inc. Increasing capture efficiency of spatial assays
US11926867B2 (en) 2019-01-06 2024-03-12 10X Genomics, Inc. Generating capture probes for spatial analysis
US11926822B1 (en) 2020-09-23 2024-03-12 10X Genomics, Inc. Three-dimensional spatial analysis
US11933957B1 (en) 2023-02-27 2024-03-19 10X Genomics, Inc. Imaging system hardware

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060057573A1 (en) * 2002-02-15 2006-03-16 Somalogic, Inc Methods and reagents for detecting target binding by nucleic acid ligands
US20070166741A1 (en) * 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US6242246B1 (en) * 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
US20020197694A1 (en) * 2001-06-20 2002-12-26 Weiping Shao Conjugates of reduced antibodies and biomolecules
US9487823B2 (en) 2002-12-20 2016-11-08 Qiagen Gmbh Nucleic acid amplification
US8043834B2 (en) * 2003-03-31 2011-10-25 Qiagen Gmbh Universal reagents for rolling circle amplification and methods of use
CA2494571C (en) * 2003-12-02 2010-02-09 F.Hoffmann-La Roche Ag Oligonucleotides containing molecular rods
CN114053429A (en) * 2004-06-01 2022-02-18 健泰科生物技术公司 Antibody-drug conjugates and methods
EP1863908B1 (en) 2005-04-01 2010-11-17 Qiagen GmbH Reverse transcription and amplification of rna with simultaneous degradation of dna
US7494776B2 (en) * 2005-07-07 2009-02-24 Beckman Coulter, Inc. Labeled complementary oligonucleotides to detect oligonucleotide-linked ligands
EP1762627A1 (en) 2005-09-09 2007-03-14 Qiagen GmbH Method for the activation of a nucleic acid for performing a polymerase reaction
HUE025489T2 (en) * 2006-01-17 2016-04-28 Somalogic Inc Multiplexed analyses of test samples
US7855054B2 (en) * 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
GB0711560D0 (en) * 2007-06-14 2007-07-25 Innova Biosciences Ltd Improvements in or relating to production of conjugates
US8906700B2 (en) 2007-11-06 2014-12-09 Ambergen, Inc. Methods and compositions for phototransfer
US20100040576A1 (en) * 2007-12-18 2010-02-18 The Texas A&M University System Modified Oligonucleotides For The Treatment Of Hepatitis C Infection
US20100112558A1 (en) * 2008-11-03 2010-05-06 Xiaolian Gao Probe Bead Synthesis and Use
WO2014030066A2 (en) 2012-08-22 2014-02-27 Bernitz Mats Nilsson Methods for identifying nucleic acid sequences
AU2014249190C1 (en) 2013-03-11 2021-11-18 Meso Scale Technologies, Llc. Improved methods for conducting multiplexed assays
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
MA45328A (en) 2016-04-01 2019-02-06 Avidity Biosciences Llc NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
KR102623786B1 (en) 2017-12-06 2024-01-11 어비디티 바이오사이언시스 인크. Compositions and methods of treating muscle atrophy and myotonic dystrophy
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
EP4121063A1 (en) 2020-03-19 2023-01-25 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
TW202216211A (en) 2020-07-01 2022-05-01 美商希沃爾拜克治療公司 Anti-asgr1 antibody conjugates and uses thereof
CA3231330A1 (en) 2021-09-16 2023-03-23 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
CN115011540A (en) * 2022-06-07 2022-09-06 清华大学深圳国际研究生院 Method for connecting protein on surface of nucleated cell and application thereof

Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536871A (en) * 1983-07-26 1985-08-20 Gte Communications Products Corporation Signal detector apparatus
US4683194A (en) * 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5270184A (en) * 1991-11-19 1993-12-14 Becton, Dickinson And Company Nucleic acid target generation
US5316906A (en) * 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
US5427930A (en) * 1990-01-26 1995-06-27 Abbott Laboratories Amplification of target nucleic acids using gap filling ligase chain reaction
US5441867A (en) * 1989-12-04 1995-08-15 Zeneca Limited Pre-activated proteins for labelling oligonucleotide probes
US5455166A (en) * 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US5552541A (en) * 1990-06-20 1996-09-03 Beckman Instruments, Inc. Haptenic probes for detecting capture polynucleotides
US5605800A (en) * 1978-04-13 1997-02-25 Institut Pasteur Method of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method
US5648213A (en) * 1994-08-30 1997-07-15 Beckman Instruments, Inc. Compositions and methods for use in detection of analytes
US5698411A (en) * 1995-05-18 1997-12-16 Coulter Corporation Method for determining activity of enzymes in metabolically active whole cells
US5733733A (en) * 1992-08-04 1998-03-31 Replicon, Inc. Methods for the isothermal amplification of nucleic acid molecules
US5854033A (en) * 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US5876928A (en) * 1978-04-13 1999-03-02 Institut Pasteur Method of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method
US5976822A (en) * 1995-05-18 1999-11-02 Coulter International Corp. Method and reagent for monitoring apoptosis and distinguishing apoptosis from necrosis
US5989823A (en) * 1998-09-18 1999-11-23 Nexstar Pharmaceuticals, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US6090552A (en) * 1996-07-16 2000-07-18 Intergen Company Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US6124120A (en) * 1997-10-08 2000-09-26 Yale University Multiple displacement amplification
US6143495A (en) * 1995-11-21 2000-11-07 Yale University Unimolecular segment amplification and sequencing
US6180338B1 (en) * 1992-08-04 2001-01-30 Beckman Coulter, Inc. Method, reagent and kit for the detection and amplification of nucleic acid sequences
US6197513B1 (en) * 1998-02-11 2001-03-06 Pe Corporation PNA and DNA conjugates and methods for preparation thereof
US6207368B1 (en) * 1992-08-04 2001-03-27 Beckman Coulter, Inc. Methods and reagents for controlling chain extension and ligation chain reactions
US6218152B1 (en) * 1992-08-04 2001-04-17 Replicon, Inc. In vitro amplification of nucleic acid molecules via circular replicons
US6251621B1 (en) * 1993-04-14 2001-06-26 Litmus Concepts, Inc. Reporter enzyme release technology: methods of assaying for the presence of aspartic proteases and other hydrolytic enzyme activities
US6261808B1 (en) * 1992-08-04 2001-07-17 Replicon, Inc. Amplification of nucleic acid molecules via circular replicons
US20030045694A1 (en) * 2000-08-11 2003-03-06 Chait Brian T. Ultra-sensitive detection systems

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3172879D1 (en) 1980-05-22 1985-12-19 Pasteur Institut Coupled product between a lectin and a specific ligand, obtention and use in the biological field
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
CA2035010C (en) 1990-01-26 1996-12-10 Keith C. Backman Method of amplifying target nucleic acids applicable to both polymerase and ligase chain reactions
CA2157902A1 (en) * 1993-03-10 1994-09-15 Christopher Douglas Valiant Black Tumour targeting with l-enantiomeric oligonucleotide conjugates of immunoreagents and of chelated radionuclides
US6111085A (en) * 1996-09-13 2000-08-29 Isis Pharmaceuticals, Inc. Carbamate-derivatized nucleosides and oligonucleosides
EP1304122A2 (en) * 1997-05-21 2003-04-23 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membrane
EP1151000A2 (en) * 1999-02-12 2001-11-07 Oklahoma Medical Research Foundation Polymeric immunoglobulin receptor (pigr)-binding domains and methods of use therefor

Patent Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605800A (en) * 1978-04-13 1997-02-25 Institut Pasteur Method of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method
US5955262A (en) * 1978-04-13 1999-09-21 Institut Pasteur Method of detecting and characterizing a nucleic acid or reactant for the application of this method
US5876928A (en) * 1978-04-13 1999-03-02 Institut Pasteur Method of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method
US4536871A (en) * 1983-07-26 1985-08-20 Gte Communications Products Corporation Signal detector apparatus
US4683194A (en) * 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683202B1 (en) * 1985-03-28 1990-11-27 Cetus Corp
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5441867A (en) * 1989-12-04 1995-08-15 Zeneca Limited Pre-activated proteins for labelling oligonucleotide probes
US5427930A (en) * 1990-01-26 1995-06-27 Abbott Laboratories Amplification of target nucleic acids using gap filling ligase chain reaction
US5552541A (en) * 1990-06-20 1996-09-03 Beckman Instruments, Inc. Haptenic probes for detecting capture polynucleotides
US5455166A (en) * 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US5316906A (en) * 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
US5443986A (en) * 1991-08-23 1995-08-22 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
US5270184A (en) * 1991-11-19 1993-12-14 Becton, Dickinson And Company Nucleic acid target generation
US5733733A (en) * 1992-08-04 1998-03-31 Replicon, Inc. Methods for the isothermal amplification of nucleic acid molecules
US6261808B1 (en) * 1992-08-04 2001-07-17 Replicon, Inc. Amplification of nucleic acid molecules via circular replicons
US6180338B1 (en) * 1992-08-04 2001-01-30 Beckman Coulter, Inc. Method, reagent and kit for the detection and amplification of nucleic acid sequences
US6218152B1 (en) * 1992-08-04 2001-04-17 Replicon, Inc. In vitro amplification of nucleic acid molecules via circular replicons
US6207368B1 (en) * 1992-08-04 2001-03-27 Beckman Coulter, Inc. Methods and reagents for controlling chain extension and ligation chain reactions
US6251621B1 (en) * 1993-04-14 2001-06-26 Litmus Concepts, Inc. Reporter enzyme release technology: methods of assaying for the presence of aspartic proteases and other hydrolytic enzyme activities
US5648213A (en) * 1994-08-30 1997-07-15 Beckman Instruments, Inc. Compositions and methods for use in detection of analytes
US5698411A (en) * 1995-05-18 1997-12-16 Coulter Corporation Method for determining activity of enzymes in metabolically active whole cells
US5976822A (en) * 1995-05-18 1999-11-02 Coulter International Corp. Method and reagent for monitoring apoptosis and distinguishing apoptosis from necrosis
US6143495A (en) * 1995-11-21 2000-11-07 Yale University Unimolecular segment amplification and sequencing
US5854033A (en) * 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6090552A (en) * 1996-07-16 2000-07-18 Intergen Company Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US6124120A (en) * 1997-10-08 2000-09-26 Yale University Multiple displacement amplification
US6197513B1 (en) * 1998-02-11 2001-03-06 Pe Corporation PNA and DNA conjugates and methods for preparation thereof
US5989823A (en) * 1998-09-18 1999-11-23 Nexstar Pharmaceuticals, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US20030045694A1 (en) * 2000-08-11 2003-03-06 Chait Brian T. Ultra-sensitive detection systems

Cited By (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038331A1 (en) * 2002-08-23 2004-02-26 Reddy M. Parameswara Solid phase synthesis of biomolecule conjugates
US20060292559A1 (en) * 2005-06-23 2006-12-28 Beckman Coulter, Inc. Cell-based microarrays, and methods for their preparation and use
US20070212337A1 (en) * 2006-02-01 2007-09-13 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
US20150218209A1 (en) * 2007-04-18 2015-08-06 Solulink, Inc. Preparation and/or Purification of Oligonucleotide Conjugates
US9222936B2 (en) 2007-04-18 2015-12-29 Solulink, Inc. Methods and/or use of oligonucleotide conjugates for suppressing background due to cross-hybridization
US20090123467A1 (en) * 2007-07-31 2009-05-14 The Johns Hopkins University Polypeptide-Nucleic Acid Conjugate for Immunoprophylaxis or Immunotherapy for Neoplastic or Infectious Disorders
US11339432B2 (en) 2009-04-30 2022-05-24 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US9085798B2 (en) 2009-04-30 2015-07-21 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US11499188B2 (en) 2009-04-30 2022-11-15 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US9783847B2 (en) 2009-04-30 2017-10-10 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US11499187B2 (en) 2009-04-30 2022-11-15 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US11352665B2 (en) 2009-04-30 2022-06-07 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US10501793B2 (en) 2009-04-30 2019-12-10 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US10000800B2 (en) 2009-04-30 2018-06-19 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US10119165B2 (en) 2009-04-30 2018-11-06 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US10266883B2 (en) 2009-04-30 2019-04-23 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US10266884B2 (en) 2009-04-30 2019-04-23 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US11447822B2 (en) 2009-04-30 2022-09-20 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
WO2011071943A1 (en) * 2009-12-07 2011-06-16 Prognosys Biosciences, Inc. Peptide display arrays
US11761030B2 (en) 2010-04-05 2023-09-19 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11067567B2 (en) 2010-04-05 2021-07-20 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10494667B2 (en) 2010-04-05 2019-12-03 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10472669B2 (en) 2010-04-05 2019-11-12 Prognosys Biosciences, Inc. Spatially encoded biological assays
US9371598B2 (en) 2010-04-05 2016-06-21 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10612079B2 (en) 2010-04-05 2020-04-07 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10619196B1 (en) 2010-04-05 2020-04-14 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10662468B2 (en) 2010-04-05 2020-05-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10662467B2 (en) 2010-04-05 2020-05-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10308982B2 (en) 2010-04-05 2019-06-04 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11767550B2 (en) 2010-04-05 2023-09-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10914730B2 (en) 2010-04-05 2021-02-09 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11401545B2 (en) 2010-04-05 2022-08-02 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10962532B2 (en) 2010-04-05 2021-03-30 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10961566B2 (en) 2010-04-05 2021-03-30 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10983113B2 (en) 2010-04-05 2021-04-20 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10982268B2 (en) 2010-04-05 2021-04-20 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10996219B2 (en) 2010-04-05 2021-05-04 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11001878B1 (en) 2010-04-05 2021-05-11 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11001879B1 (en) 2010-04-05 2021-05-11 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11008607B2 (en) 2010-04-05 2021-05-18 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11732292B2 (en) 2010-04-05 2023-08-22 Prognosys Biosciences, Inc. Spatially encoded biological assays correlating target nucleic acid to tissue section location
US10480022B2 (en) 2010-04-05 2019-11-19 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11384386B2 (en) 2010-04-05 2022-07-12 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11733238B2 (en) 2010-04-05 2023-08-22 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11156603B2 (en) 2010-04-05 2021-10-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11634756B2 (en) 2010-04-05 2023-04-25 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11208684B2 (en) 2010-04-05 2021-12-28 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11371086B2 (en) 2010-04-05 2022-06-28 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11560587B2 (en) 2010-04-05 2023-01-24 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11293917B2 (en) 2010-04-05 2022-04-05 Prognosys Biosciences, Inc. Systems for analyzing target biological molecules via sample imaging and delivery of probes to substrate wells
US11549138B2 (en) 2010-04-05 2023-01-10 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11313856B2 (en) 2010-04-05 2022-04-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11542543B2 (en) 2010-04-05 2023-01-03 Prognosys Biosciences, Inc. System for analyzing targets of a tissue section
US11365442B2 (en) 2010-04-05 2022-06-21 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11519022B2 (en) 2010-04-05 2022-12-06 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11866770B2 (en) 2010-04-05 2024-01-09 Prognosys Biosciences, Inc. Spatially encoded biological assays
US9958454B2 (en) 2011-04-08 2018-05-01 Prognosys Biosciences, Inc. Peptide constructs and assay systems
US11340232B2 (en) 2011-04-08 2022-05-24 Prognosys Biosciences, Inc. Peptide constructs and assay systems
US11352659B2 (en) 2011-04-13 2022-06-07 Spatial Transcriptomics Ab Methods of detecting analytes
US11795498B2 (en) 2011-04-13 2023-10-24 10X Genomics Sweden Ab Methods of detecting analytes
US11788122B2 (en) 2011-04-13 2023-10-17 10X Genomics Sweden Ab Methods of detecting analytes
US11479809B2 (en) 2011-04-13 2022-10-25 Spatial Transcriptomics Ab Methods of detecting analytes
US11231419B2 (en) 2013-03-15 2022-01-25 Prognosys Biosciences, Inc. Methods for detecting peptide/MHC/TCR binding
US11092601B2 (en) 2013-03-15 2021-08-17 Prognosys Biosciences, Inc. Methods for detecting peptide/MHC/TCR binding
US11913952B2 (en) 2013-03-15 2024-02-27 Prognosys Biosciences, Inc. Methods for detecting peptide/MHC/TCR binding
US10774372B2 (en) 2013-06-25 2020-09-15 Prognosy s Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11286515B2 (en) 2013-06-25 2022-03-29 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11753674B2 (en) 2013-06-25 2023-09-12 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US9868979B2 (en) 2013-06-25 2018-01-16 Prognosys Biosciences, Inc. Spatially encoded biological assays using a microfluidic device
US9879313B2 (en) 2013-06-25 2018-01-30 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11046996B1 (en) 2013-06-25 2021-06-29 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US10927403B2 (en) 2013-06-25 2021-02-23 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11618918B2 (en) 2013-06-25 2023-04-04 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11359228B2 (en) 2013-06-25 2022-06-14 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11821024B2 (en) 2013-06-25 2023-11-21 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US10288608B2 (en) 2013-11-08 2019-05-14 Prognosys Biosciences, Inc. Polynucleotide conjugates and methods for analyte detection
US11162132B2 (en) 2015-04-10 2021-11-02 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11390912B2 (en) 2015-04-10 2022-07-19 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11739372B2 (en) 2015-04-10 2023-08-29 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11299774B2 (en) 2015-04-10 2022-04-12 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US10774374B2 (en) 2015-04-10 2020-09-15 Spatial Transcriptomics AB and Illumina, Inc. Spatially distinguished, multiplex nucleic acid analysis of biological specimens
WO2020018739A1 (en) * 2018-07-18 2020-01-23 University Of Florida Research Foundation Rna silencing nanozymes
US11519033B2 (en) 2018-08-28 2022-12-06 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample
US11753675B2 (en) 2019-01-06 2023-09-12 10X Genomics, Inc. Generating capture probes for spatial analysis
US11649485B2 (en) 2019-01-06 2023-05-16 10X Genomics, Inc. Generating capture probes for spatial analysis
US11926867B2 (en) 2019-01-06 2024-03-12 10X Genomics, Inc. Generating capture probes for spatial analysis
US11702698B2 (en) 2019-11-08 2023-07-18 10X Genomics, Inc. Enhancing specificity of analyte binding
US11505828B2 (en) 2019-12-23 2022-11-22 10X Genomics, Inc. Methods for spatial analysis using RNA-templated ligation
US11795507B2 (en) 2019-12-23 2023-10-24 10X Genomics, Inc. Methods for spatial analysis using RNA-templated ligation
US11332790B2 (en) 2019-12-23 2022-05-17 10X Genomics, Inc. Methods for spatial analysis using RNA-templated ligation
US11732299B2 (en) 2020-01-21 2023-08-22 10X Genomics, Inc. Spatial assays with perturbed cells
US11702693B2 (en) 2020-01-21 2023-07-18 10X Genomics, Inc. Methods for printing cells and generating arrays of barcoded cells
US11898205B2 (en) 2020-02-03 2024-02-13 10X Genomics, Inc. Increasing capture efficiency of spatial assays
US11732300B2 (en) 2020-02-05 2023-08-22 10X Genomics, Inc. Increasing efficiency of spatial analysis in a biological sample
US11891654B2 (en) 2020-02-24 2024-02-06 10X Genomics, Inc. Methods of making gene expression libraries
WO2021211791A1 (en) * 2020-04-15 2021-10-21 Academia Sinica Oligonucleotide conjugates and preparation and applications thereof
US11535887B2 (en) 2020-04-22 2022-12-27 10X Genomics, Inc. Methods for spatial analysis using targeted RNA depletion
US11773433B2 (en) 2020-04-22 2023-10-03 10X Genomics, Inc. Methods for spatial analysis using targeted RNA depletion
US11624086B2 (en) 2020-05-22 2023-04-11 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
US11608520B2 (en) 2020-05-22 2023-03-21 10X Genomics, Inc. Spatial analysis to detect sequence variants
US11866767B2 (en) 2020-05-22 2024-01-09 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
US11560592B2 (en) 2020-05-26 2023-01-24 10X Genomics, Inc. Method for resetting an array
US11492612B1 (en) 2020-06-08 2022-11-08 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
US11624063B2 (en) 2020-06-08 2023-04-11 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
US11781130B2 (en) 2020-06-08 2023-10-10 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
US11407992B2 (en) 2020-06-08 2022-08-09 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
US11434524B2 (en) 2020-06-10 2022-09-06 10X Genomics, Inc. Methods for determining a location of an analyte in a biological sample
US11661626B2 (en) 2020-06-25 2023-05-30 10X Genomics, Inc. Spatial analysis of DNA methylation
US11408029B2 (en) 2020-06-25 2022-08-09 10X Genomics, Inc. Spatial analysis of DNA methylation
US11761038B1 (en) 2020-07-06 2023-09-19 10X Genomics, Inc. Methods for identifying a location of an RNA in a biological sample
US11926822B1 (en) 2020-09-23 2024-03-12 10X Genomics, Inc. Three-dimensional spatial analysis
US11827935B1 (en) 2020-11-19 2023-11-28 10X Genomics, Inc. Methods for spatial analysis using rolling circle amplification and detection probes
US11618897B2 (en) 2020-12-21 2023-04-04 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
US11873482B2 (en) 2020-12-21 2024-01-16 10X Genomics, Inc. Methods, compositions, and systems for spatial analysis of analytes in a biological sample
US11680260B2 (en) 2020-12-21 2023-06-20 10X Genomics, Inc. Methods, compositions, and systems for spatial analysis of analytes in a biological sample
US11840724B2 (en) 2021-09-01 2023-12-12 10X Genomics, Inc. Methods, compositions, and kits for blocking a capture probe on a spatial array
US11753673B2 (en) 2021-09-01 2023-09-12 10X Genomics, Inc. Methods, compositions, and kits for blocking a capture probe on a spatial array
US11933957B1 (en) 2023-02-27 2024-03-19 10X Genomics, Inc. Imaging system hardware

Also Published As

Publication number Publication date
WO2003035830A2 (en) 2003-05-01
US20030092901A1 (en) 2003-05-15
US6942972B2 (en) 2005-09-13
WO2003035830A3 (en) 2004-08-26
EP1485500A4 (en) 2005-12-07
EP1485500A2 (en) 2004-12-15
AU2002332090A1 (en) 2003-05-06

Similar Documents

Publication Publication Date Title
US6942972B2 (en) Efficient synthesis of protein-oligonucleotide conjugates
US20210163623A1 (en) Modified Antibody, Antibody-Conjugate and Process For The Preparation Thereof
US5391723A (en) Oligonucleotide conjugates
US9340824B2 (en) Immunohistochemistry detection method
AU2006239315B2 (en) Enzymes conjugated to antiobodies via a PEG heterobifuctional linker
KR20200041912A (en) 6-amino-7,9-dihydro-8H-purin-8-one derivative as an immunostimulant toll-like receptor 7 (TLR7) agonist
US20160257764A1 (en) Glycoengineered antibody, antibody-conjugate and methods for their preparation
KR101290034B1 (en) Method of detecting target substances
JPH0535990B2 (en)
US20090208932A1 (en) Methods Of Detecting An Analyte In A Sample
JPH04334377A (en) Acid-instable linker molecule
EP0307480A1 (en) Process for preparing antibody complex
US20060292559A1 (en) Cell-based microarrays, and methods for their preparation and use
Thornlow et al. Dual site-specific antibody conjugates for sequential and orthogonal cargo release
EA010506B1 (en) Methods, kits and compositions for the development and use of monoclonal antibodies specific to antigenes of low immunogenicity
JP2613203B2 (en) Solution-phase single-cross assays for detection of polynucleotide sequences
Chollet Selective attachment of oligonucleotides to interleukin-1β and targeted delivery to cells
JP3150158B2 (en) Preactivated proteins for oligonucleotide probe labeling
JPS6257220B2 (en)
KR102182985B1 (en) Drug Delivery System Using pH-dependent Membrane Penetrating Peptide and Drug Conjugate Thereof
US10036066B2 (en) In situ hybridization detection method
Miyagi et al. Synthesis of desmosine-BSA/KLH conjugates via Sonogashira/Negishi cross-coupling reactions
US20230194509A1 (en) Efficient antibody dna-barcoding reagents for multiplexed molecular imaging
WO2017097973A1 (en) Modified nucleosides
US7189393B2 (en) Recombinant anti-tumor RNAse

Legal Events

Date Code Title Description
AS Assignment

Owner name: BECKMAN COULTER, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FAROOQUI, FIRDOUS;REDDY, M. PARAMESWARA;REEL/FRAME:016406/0037

Effective date: 20011023

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION